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Abstract 
The compromise of quality of life (QoL) in Huntington’s disease (HD) is a major issue, both 
for individuals with the disease as well as for their caregivers. The International Parkinson 
and Movement Disorder Society (MDS) commissioned a review of the use and clinimetric 
validation status of measures used in HD to assess aspects related with QoL, and to make 
recommendations on their use following standardized criteria. We included both patient-
centered measures (patient Health-related (HR) QoL measures) and caregiver-centered 
measures (caregiver QoL measures). After conducting a systematic literature search, we 
included 12 measures of patient HRQoL and 2 measures of caregiver QoL. Regarding patient-
centered measures, the Medical Outcomes Study 36-Item Short-Form Health Survey is 
“recommended” as a generic assessment of HRQoL in patients with HD. The 12-Item Short 
Form Health Survey, the Sickness Impact Profile, the 12-item World Health 
Organization Disability Assessment Schedule, and the Huntington's Disease Health-Related 
Quality of Life questionnaire are “suggested”. No caregiver-centered QoL measure obtained a 
“recommended” status.  The Alzheimer’s Carer’s Quality of Life Inventory and the 
Huntington's Disease Quality of Life Battery for Carers are “suggested”. Recognizing that the 
assessment of patient HRQoL can be challenging in HD, as patients may lack insight and 
there is insufficient clinimetric testing of these scales, the committee concluded that further 
validation of currently available HRQoL measures should be undertaken, namely, those HD-
specific HRQoL measures that have recently been reported and used. 
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INTRODUCTION 
Huntington’s disease (HD) is a complex neurodegenerative disorder in which motor, 
cognitive and behavioral manifestations have a significant impact on health-related quality of 
life (HRQoL) of patients. The concept of HRQoL has been developed to express the aspects 
of overall quality of life (QoL) that can be clearly shown to be related to health, be that 
physical or mental.
1
 The World Health Organization (WHO) defines health as "a state of 
complete physical, mental, and social well-being not merely the absence of disease.”
2
 The 
WHO lists the following functioning domains as being part of HRQoL: physical, social, 
relational, and emotional well-being.
1
 Although, the term “QoL” is often used 
interchangeably with the term “HRQoL”, QoL is a much broader multidimensional concept. 
The WHO defines QoL as “the individuals’ perception of their position in life in the context 
of the culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns”.
1
 Another important concept that is often used in QoL literature is 
health status (HS). HS is defined as the perceived health in descriptive terms of physical and 
mental symptoms, disability, and social dysfunction related to the health condition.
3
 It is 
different from HRQoL in that it lacks judgments and reactions.
3
 As stated in a similar review 
for HRQoL measures used in Parkinson’s disease, it is reasonable to consider HS as a relevant 
factor for HRQoL, which is a component of QoL in general.
4
   
HRQoL is an important patient-reported outcome that constitutes a core assessment of the 
efficacy of clinical interventions in HD, as these interventions ideally seek to not only 
improve patients’ symptoms, but ultimately to improve patient QoL. It is therefore important 
that valid and reliable measures are available that can be used in HD. In addition to measures 
centered on patients (patient-centered HRQoL measures), the sub-committee the authors 
decided we also to included measures centered on caregivers and their own QoL (caregiver-
centered QoL measures), recognizing that HD impacts the “global” QoL of caregivers and a 
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potential change in QoL is not necessarily related to health and may include other aspects of 
life.
5, 6
  
 
METHODS 
Organization and critique process 
The Committee on Rating Scales Development of the MDS appointed a team of 10 members 
(sub-committee) to review clinical measures used in HD to assess HRQoL measures; these 
members included specialists in HD, and an expert in scale development and clinimetrics 
(A.M.D.). Two sub-committee members evaluated each measure. If a sub-committee member 
was involved in the development of a measure, he/she was not involved in its review. Data 
were extracted into a proforma provided by the MDS and adapted for the purpose of the 
current review. The assessment of the measure included the description of the measure, its 
availability, context of use, and reported clinimetric properties in patients with HD.  All sub-
committee members jointly assessed the completed r views of the measures. Any unresolved 
issues and limitations of the critiqued measures were identified for discussion and reporting. 
The final recommendations were based on consensus among the sub-committee members and 
the liaison member of the Committee on Rating Scales Development of the MDS (E.C.). 
 
Selection of measures 
The methodology for this review was modeled on a previously used methodology.
7
 A 
literature search was performed using Medline on PubMed, Web of Science, EMBASE, and 
Psychinfo. The keywords used in the search included: “Huntington*” OR “Westphal variant” 
OR “juvenile Huntington*”, and the terms “scale” OR “questionnaire” OR “index” OR 
“measure” as well as the keywords: ”Quality of life”, “QoL”, “health-related quality of life”, 
Page 5 of 146
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 6
“HRQoL”, “health status”. For each identified clinical measure, a search was conducted for 
the terms “Huntington's disease,” or “Huntington disease” or “Huntington*” and the name of 
the measure.  Manuscripts published before October 17, 2016 were retrieved using the above 
search strategy and thoroughly screened by the chair of the sub-committee (T.A.M.) to 
ascertain which measure had been used in each study.  
 
Inclusion/exclusion for review 
Measures used at least nce in HD populations (patients at risk, presymptomatic gene carriers, 
and symptomatic HD patients) were included. Measures were excluded from review if they 
were not available in English, were only mentioned in reviews but not used in an original 
study, were created for a specific study without any information about their structure or use, 
or if the full-paper was not available (e.g., abstract format only). In terms of construct of 
measures, the sub-committee decided to include all measures proposed by developers to 
capture HRQoL, QoL or HS that have been used in HD studies.  
 
Criteria for rating  
We followed the Classification System for Scale Recommendation used by the MDS that uses 
three criteria: (1) Use in HD populations; (2) Use in HD by groups other than the original 
developers and data on its use are available; (3) The available clinimetric/psychometric data 
in HD support the goals of measurement of severity (e.g., evaluation of reliability, construct 
validity, and score discrimination across levels of symptom severity). Specific to this review, 
while HrQoL is not a symptom per se, it reflects the multidimensional construct of the impact 
of a disease/condition on QoL. The ability to differentiate across different levels of severity 
still stands as fundamental for a valid assessment of HrQoL (or caregiver QoL) in 
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observational studies or clinical trials. (for further details, see Table 1.) 
 
RESULTS  
Identified Measures and Their Use in Clinical Research 
A total of 19 clinical measures that have been used in HD research studies were identified. 
One of these measures was excluded after abstract review due to inadequacy of measure 
construct (see supplementary material). The remaining 18 clinical measures were included for 
an in-depth review. Four measures were excluded because: 1) their sole use in HD was in case 
series without any clinimetric data available (the Manchester Assessment of Quality of Life, 
the Fatigue Impact scale), 2) it was created solely for a single study (a Non-Standardized QoL 
question), and 3) the proposed construct was inadequate for the current review (the Caregiver 
Burden Inventory). We grouped the 14 remaining measures into patient-centered HRQoL 
measures (n=12) and caregiver-centered QoL measures (n=2).  
For patient-centered HRQoL measures, only The Medical Outcomes Study 36-Item Short-
Form Health Survey was (SF-36) received a classification of “recommended” as a generic 
assessment of health status in manifest HD (severity). The 12-Item Short Form Health Survey 
(SF-12), the Sickness Impact Profile (SIP), the Huntington’s Disease Health-Related Quality 
of Life Questionnaire (HDQoL), and the 12-item World Health Organization Disability 
Assessment Schedule (WHODAS 2.0), were classified as “suggested” (see supplementary 
material for overview of all assessments classified as “suggested with caveats” or “listed”). 
For caregiver-centered QoL measures, no measure was “recommended” for any of the 
purposes considered in this review. The Alzheimer’s Carer’s Quality of Life Inventory 
(AQLI), and the Huntington's Disease Quality of Life Battery for Carers (HD-QoL-C) were 
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classified as “suggested” (see supplementary material for overview of all assessments 
classified as “suggested with caveats” or “listed”). 
 
Patient-centered HRQoL rating scales  
 
Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) 
The SF-36 is an easy-to-administer self-reported set of generic measures of patient health 
status developed by the RAND Corporation as part of the Medical Outcomes Study (MOS). 
The SF-36 assesses eight functional dimensions: physical functioning, physical role 
limitations, mental health, emotional role limitations, social functioning, energy/vitality, pain, 
and general health perceptions, which can be summarized into two scores (physical and 
mental) and a global utility index.8 The SF-36 has been widely used in HD
9-12
, and the vast 
majority of the data was collected using version 1 of SF-36. The most current SF-36 version 2 
has less ambiguous wording, improved layout, enhanced response choices for some items, 
and increased cross-cultural validity. 
Internal consistency has been shown for the SF-36 subscales, and domain and component 
scores (Cronbach’s alpha ≥0.80).
9-12
 The test-retest reliability coefficients, as measured by 
Intra-Class Coefficient (ICC), have been reported to be > 0.70 for all domains, apart from the 
“emotional role” domain (ICC= 0.63). The Mental Health summary score has been shown to 
correlate only with the Beck Depression Inventory (BDI), while the Physical Health summary 
score of the SF-36 correlates with the BDI and a patient’s self-rated and clinician’s rating of 
patients’ level of functioning/independence level, but no factor analysis has been conducted 
for the SF-36 in this population. The SF-36 (total score, Vitality score, and Mental 
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Component Score) have been shown to be sensitive to change in manifest HD clinical trials
9
 
11, 13
  
Recommendation: The SF-36 is “recommended” as a generic assessment of health status in 
manifest HD (severity). The physical summary score seems to have better construct validity 
in HD. It is not known if the more recent SF-36 Version 2 performs equally well in HD as the 
SF-36 Version 1.  
 
Medical Outcomes Study 12-Item Short-Form Health Survey (SF-12) 
The SF-12 is a 12-item shorter version of the SF-36. It covers the same functional dimensions 
as the SF-36 but includes fewer items, and thus, is quicker to administer (2 minutes vs. 8-12 
minutes for the SF-36).
14
 It has been used less extensively in HD than the SF-36.
8
 It is 
currently being used in Enroll-HD but no data have been reported.
15
 Various degrees of 
convergent validity have been reported between the SF-12 Physical and Mental Health 
components, and the components of the HD-PRO-Triad (SF-12 physical component, 
Pearson’s correlations: motor, -0.79; cognition -0.77; emotion/behavioral dyscontrol -0.47; 
total score -0.76. SF-12 mental component, cognition -0.61; motor -0.51; total score -0.61), 
and emotion/behavioral dyscontrol (Pearson’s correlation: -0.53, all p<0.05).
16
 The SF-12 
Physical component, but not the Mental Health component, has been shown to be sensitive to 
change following multidisciplinary rehabilitation.
17
 
Recommendation: The SF-12 is “suggested” as a generic assessment of health status in 
manifest HD (severity), as it lacks test-retest reliability data and internal consistency data. 
 
Sickness Impact Profile (SIP) 136 items 
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The SIP is a generic measure of self-reported health status,
18
 consisting of 136 items covering 
12 categories grouped into two subscales (physical and psychosocial). Scores are presented as 
a percentage of maximal dysfunction ranging from 0 to 100; a higher score indicates a higher 
level of dysfunction. The SIP can take up to 30 minutes to complete. The SIP has been used in 
two studies in manifest HD,
19, 20
 and a modified version using only 3 of the 12 categories was 
used in trial for cognition in HD.
21
 Internal consistency has been reported to be high 
(Cronbach’s alpha > 0.80),
19
 as has test-retest reliability (ICC> 0.70) for scores of subscales 
and all categories, aside from the “emotional behavior” (ICC=0.49) and “work” (ICC=0.68) 
categories.
19
 The SIP total score has been shown to correlate with both the patient’s self-rated 
(Spearman’s correlation: -0.69) and clinician’s rating (Spearman’s correlation: -0.64) of 
patients’ level of functioning/independence (all p< 0.01), with the BDI (Spearman’s 
correlation: 0.47, p<0.01), and with the Unified Huntington’s Disease Rating Scale – Total 
Motor Score (UHDRS-TMS) (Spearman’s correlation: 0.32, p<0.05). The Psychosocial 
subscale has been shown to correlate with both the patient’s self-rated and the clinician’s 
rating of patients’ level of functioning/independence, while the Physical subscale has been 
shown to correlate with both the BDI and the UHDRS-TMS, in addition to both the patient’s 
self-rated and the clinician’s rating of patients’ level of functioning/independence. 
19
 In a 
head-to-head comparison with the SF-36, the SIP was shown to have a worse clinimetric 
performance with less robust construct validity and test–retest reliability. In addition, motor 
symptoms appeared to influence some strictly non-motor dimensions of the SIP.
19
  
Recommendation: The SIP is “suggested” for assessing health status in manifest HD 
(severity). There are limited clinimetric data on its use in HD, and it performs worse than the 
SF-36 in a head-to-head comparison.  
 
World Health Organization Disability Assessment Schedule (WHODAS) 2.0 (12-item) 
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The WHODAS 2.0 was developed by the World Health Organization (WHO) is often 
considered a generic function-related measure of health status and consequently it was 
decided by consensus to include it in this review and not in the review of measures for 
assessment of functional ability in HD. The WHODAS 2.0 can be administered as 
interviewer-, self-, and proxy-administered forms. The WHODAS 2.0 12-item version, which 
is reviewed here, takes 5 minutes to complete and covers 6 domains: cognition, mobility, self-
care, getting along, life activities, and participation. The WHODAS 2.0 12-item has been used 
in three studies including both pre-manifest and manifest HD.
22-24
 Internal consistency has 
been shown with a Cronbach's alpha of 0.94 (95% CI: 0.93 - 0.94).
22
 Moderate convergent 
validity has been reported between the WHODAS 2.0 and other health-related quality of life 
assessments such as the RAND-12 (Pearson correlations ranging from - 0.76 to -0.41), and 
the EuroQol Five-dimension questionnaire (EQ-5D; Pearson correlations ranging from = - 
0.65 and -0.49).
22
 The scores in the WHODAS 2.0 differ significantly across the disease 
spectrum from the pre-manifest stage to late HD.
22
 In pre-manifest HD, cross-sectional 
differences between low-, mid- and high- disease burden groups have been reported.
23
 In pre-
manifest HD, only the companion-rated (proxy) version of the WHODAS 2.0 has been shown 
to be sensitive to change over a period of three years.
23
 
Recommendation: The WHODAS 2.0 12-item is “suggested” for assessing health status in 
HD (severity), as it lacks important clinimetric development in HD, namely, for test-retest 
reliability testing and requires more robust construct validity.  
 
The Huntington's Disease Health-Related Quality of Life Questionnaire (HDQoL) 
The HDQoL is a patient-reported questionnaire that was specifically developed for use in HD 
to assess HRQoL.
25
 The HDQoL covers three main domains: “primary physical and 
cognitive”, “primary emotions and self”, and “primary services”.
25
 It takes about 22 minutes 
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to complete. The HDQoL has been used in one study by authors
26
other than the group
25, 27
 
who originally developed it. The internal consistency of each of the domains has been shown 
to vary: “primary services” (Cronbach’s alpha = 0.76), “primary emotions and self” 
(Cronbach’s alpha = 0.89), and “primary physical and cognitive” (Cronbach’s alpha = 0.96). 
Test-retest reliability has been reported, but as this was evaluated with Cronbach’s alpha it 
does not provide a true adequate measure of concordance.
25
 Item ceiling effects range from 
12.5% to 50%.25 
Recommendation: The HDQoL is “suggested” for assessment of HRQoL in HD (severity), 
as there are limited clinimetric data, namely related with construct validity and test-retest 
reliability. 
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Caregiver-centered QoL measures 
 
The Alzheimer’s Carer’s Quality of Life Inventory (ACQLI) 
The ACQLI was developed to assess caregiver QoL in Alzheimer’s disease (AD).
28
 It is a 
quick (<5 minutes) questionnaire that consists of 30 items to which the caregiver answers true 
or not true; 1 point is given for each true answer, giving a possible total score of 30. The 
ACQLI has been used in a single HD study, in a head-to-head comparison with the HD-QoL-
C. The ACQLI 
29
 showed excellent internal consistency (Cronbach alpha = 0.95).
29
  
Recommendation: The ACQLI is “suggested” for assessing QoL for HD caregivers 
(severity), as its use in HD is limited to a single study in HD and clinimetric data in HD are 
limited to internal consistency.  
 
Huntington's Disease Quality of Life Battery for Carers (HD-QoL-C) 
The HD-QoL-C is a HD-specific, multi-dimensional measure for family or caregivers of 
patients with HD. It is based upon the domains and facets of the Comprehensive Quality of 
Life Scale for Adults (ComQol-A5).
30
 Two versions are available: a long-form that consists of 
34 items which incorporate measures on “practical aspects of caregiving” (n=9), “satisfaction 
with life” (n=8) and “feelings about living with HD” (n=17), and a short-form that consists of 
20 items (3 items on “satisfaction of life”, and 17 items on “feelings about living with HD”).
29
 
The HD-QoL-C has been used in four studies in HD.
9, 29, 31, 32
 Internal consistency of the long-
form has been shown for the domains “satisfaction with life” (Cronbach’s alpha = 0.91) and 
“feelings about living with HD” (Cronbach’s alpha = 0.84), but not for the domain “practical 
aspects of caregiving” (Cronbach’s alpha = 0.62).
29
 For the short-form, internal consistency 
has been shown (“satisfaction with life”, 0.92; total score, 0.88).
29
 A low correlation has been 
reported between the HD-QoL-C and the WHO Quality of Life Short Form (WHO-QoL 
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BREF),
32
 and the Huntington Quality of Life Instrument (H-QoL-I; correlations 0.22 to 0.28, 
all p<0.01). 
31
 
Recommendation: The HD-QoL-C is “suggested” for assessing QoL for HD caregivers 
(severity). It warrants further additional clinimetric development, namely in terms of 
validity, reliability and data reproducibility by other groups.  
 
Discussion 
 
We report here the results of an in-depth review of 12 measures used in HD studies to 
evaluate patient-centered HRQoL. The SF-36 is the only measure that can be classified as 
“recommended” to measure patient’s HRQoL in terms of severity. None of the HRQoL 
measures developed specifically for HD have undergone sufficient clinimetric development to 
warrant a similar classification level. There were no HRQoL measures recommended to 
measure change of intensity severity over time. Regarding patient-centered HRQoL 
measures, the sub-committee identified the following topics that warrant consideration when 
developing these types of measures:  
1) The inherent subjective nature of self-reporting HRQoL warrants a special comment 
as HD patients often lack insight regarding the presence or severity of their symptoms. 
Along the same lines, the progressive cognitive impairment experienced by HD 
patients is likely to introduce additional difficulties in ensuring the reliability of 
patient-reported HRQoL in HD, namely, at later stages. Proxy reporting was rarely 
included in the measures reviewed here and could be further assessed and considered 
as a strategy to mitigate the above-mentioned limitations of patient-reported outcomes 
in HD. 
2) As HD is a rare disease, studies often require a multi-center multi-national design that 
raises the need for validation of HRQoL and QoL measures across different cultures. 
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In this review, there were no data available on a formal cross-cultural validation for 
any of the included measures when applied to HD populations. Consequently, cross-
cultural validation should be implemented in future development programs of HRQoL 
measures in HD.  
3) We discussed the need for a generic measure vs. a disease-specific measure. Given the 
complexity of the clinical presentation of HD, it is likely that a generic scale will not 
capture all the disease features that significantly impact on the HRQoL of these 
patients, and thus a disease-specific measure may be better positioned to capture 
HRQoL in HD in a valid manner. On the other hand, although disease-specific 
measures are usually more sensitive, generic measures are able to capture global 
aspects of health that may be overlooked by the specific scales. A disease-specific 
measure that incorporates items likely found in generic measures is possibly the best 
approach.  
 
The committee also looked at caregiver-centered QoL measures. We recognize that these 
measures have their own issues. In this review, we included two caregiver-centered QoL 
measures, one developed in Alzheimer’s disease and another specifically developed for HD. 
Although caregivers play a role in caring for patients with a wide range of neurodegenerative 
disorders, and there are many features in common between caring for such patients and caring 
for a progressively dependent patient, there are limited data available to determine if 
similarities across neurodegenerative disorders are sufficient to warrant a general QoL scale 
or whether caregiver QoL needs to be disease-specific. A caregiver-centered measure that 
considers both disease-specific items and more generic items would likely be the best 
approach. 
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In the current review we identified several measures that were ‘listed’. In many cases, these 
measures have had limited evaluation of their measurement properties in HD. Still, other 
recently developed HD-specific measures are in the initial stages of comprehensive 
measurement property testing, these include the HDQLIFE, the HDQoL, or HD-PRO-
TRIAD.  Importantly, some of these newer measures incorporate patient stakeholders in their 
development, a contribution deemed essential by regulatory agencies such as the US Food and 
Drug Administration (FDA) for patient-reported outcomes supporting labeling claims.
33
 
Further testing of the measurement properties and uptake of these measures by groups other 
than the developers is required to determine their real value in evaluating HRQoL in HD 
patients. The committee concluded that the evaluation of the measurement properties of the 
currently available measures that are included in this review, namely those developed 
specifically for HD, is warranted. This should be a priority for HD researchers, considering 
for example the increasing importance of patient-reported outcomes in the development of 
novel therapies and their subsequent approval by regulatory authorities. 
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Table 1: Classification System for Scale Recommendation 
 
Category Criteria 
“Recommended” (1) Scale has been used in HD populations. 
(2) Use in HD by groups other than the original developers and data on its use were available.* 
(3) The available clinimetric/psychometric data in HD support the goals of screening (e.g., 
evaluation of sensitivity/specificity, score cut-off points, and reliability) or measurement of severity 
(e.g., evaluation of reliability, construct validity, and score discrimination across levels of symptom 
severity). 
“Suggested” (1) Scale has been used in HD populations. 
(2) Only one other criteria (2) or (3) from the above recommended category applies. 
“Listed” (1) Scale has been applied to HD populations, but no further criterion met. 
HD=Huntington’s Disease, * For rating scales not originally developed for use in HD, criterion 2 was 
fulfilled if used in at least one group in HD that reported any kind of clinimetric/psychometric data in HD.  
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Table 2:  Summary of all included scales in HD 
 
Scale/Questionnaire Developed 
for use in 
HD 
Scale has been 
applied to HD 
populations 
Used by other 
groups beyond 
the original 
developing 
group 
Appropriate 
clinimetric 
testing in HD 
Recommendation level Comments 
PATIENT-CENTERED ASSESSMENTS  
Medical Outcomes Study 36-
Item Short-Form Health 
Survey (SF-36) 
No Yes Yes Yes Recommended  
as a generic assessment 
of health status in 
manifest HD (severity) 
Most of the 
clinimetric data in 
HD were generated 
using older Version 
1. 
Medical Outcomes Study 12-
Item Short-Form Health 
Survey (SF-12) 
No Yes Yes No Suggested  
as a generic assessment 
of health status in 
manifest HD (severity) 
 
Sickness Impact Profile (SIP) 
 
No Yes Yes No Suggested  
for assessing perceived 
health status in manifest 
HD (severity) 
 
12-item World Health 
Organization Disability 
Assessment Schedule 
(WHODAS) 2.0 
No Yes Yes No Suggested for assessing 
health status in HD 
(severity) 
 
The Huntington's Disease 
health-related Quality of Life 
questionnaire (HDQoL) 
Yes Yes Yes No Suggested  
for assessment of health-
related QoL in HD 
(severity) 
 
EQ-5D 
 
No Yes Yes No Suggested with caveats Minimal 
clinimetric data 
available 
RAND-12 Health Status 
Inventory (HIS) 
 
No Yes Yes No Suggested with caveats Used in a single 
study 
Neuro-Quality of Life No Yes Yes No Suggested with caveats Used in a single 
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(Neuro-QoL) 
 
study 
PROMIS Global Health 
(PROMIS) 
No Yes Yes No Suggested with caveats Used in a single 
study 
Huntington Disease Health-
Related Quality of Life 
(HDQLIFE) 
Yes Yes No No Listed  
WHO-Quality of Life-BREF 
(WHOQOL-BREF) 
No Yes No No Listed  
Quality of Life Index  
(QoL Index) 
No Yes No No Listed  
Huntington Quality of Life 
Instrument (H-QoL-I) 
Yes Yes No No Listed  
HD-PRO-TRIAD Yes Yes No No Listed  
CAREGIVER-CENTERED ASSESSMENTS  
The Alzheimer’s Carer’s 
Quality of Life Inventory 
(AQLI) 
No Yes Yes No Suggested for assessing 
quality of life for HD 
caregivers  
(severity) 
 
Huntington's Disease Quality 
of Life Battery for Carers 
(HD-QoL-C) 
Yes Yes Yes No Suggested for assessing 
quality of life for HD 
caregivers  
(severity) 
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Table 3. Summary of clinimetric data of all instruments used in HD with a recommendation level of “recommended” or “suggested” 
 
SCALE 
INTERNAL 
CONSISTENCY 
TEST-
RETEST 
RELIABILITY  
CONSTRUCT 
VALIDITY 
GROUP 
KNOWN 
VALIDITY  
RESPONSIVENESS 
CEILING 
/FLOOR 
EFFECT 
SENSITIVITY/ 
SPECIFICITY 
TRANSLATION 
STATUS** 
PATIENT-CENTERED ASSESSMENTS  
Medical 
Outcomes 
Study 36-
Item Short-
Form Health 
Survey (SF-
36) * 
+ + + + +/- NR NR Widespread 
Medical 
Outcomes 
Study 12-
Item Short-
Form Health 
Survey (SF-
12) 
- - + + +/- NR NR Widespread 
Sickness 
Impact 
Profile  
+ +/-  +/-  - NR NR NR English 
12-item 
World 
Health 
Organization 
Disability 
Assessment 
Schedule 
+ NR +/- + NR ceiling effect NR Widespread 
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The 
Huntington's 
Disease 
health-
related 
Quality of 
Life 
questionnaire  
+ + +/-  - -  ceiling effect  NR English  
CAREGIVER-CENTERED ASSESSMENTS  
The 
Alzheimer’s 
Carer’s 
Quality of 
Life 
Inventory  
+ NR NR NR NR 
acceptable 
floor and 
ceiling effect 
NR 
English, French, 
German, Italian, 
Spanish. 
Huntington's 
Disease 
Quality of 
Life Battery 
for Carers  
+ +/- 
+/-  
(sparse) 
NR NR 
acceptable 
floor and 
ceiling effect 
NR 
English, French 
Italian 
HD –Huntington’s disease. NR – not reported. (+) - good performance, (+/-) contradictory data or very limited data (-) poor performance.  
NOTE: data regarding Minimally Clinically Important Difference was not assessed in any of the scales.  
* The SF-36 was the only rating scale “recommended”. Remaining scales were “suggested”. ** We list the languages officially recognized as being 
used for scale translation, widespread = scale translation has been recognized in more than 5 languages 
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Abstract 
The compromise of quality of life (QoL) in Huntington’s disease (HD) is a major issue, both 
for individuals with the disease as well as for their caregivers. The International Parkinson 
and Movement Disorder Society (MDS) commissioned a review of the use and clinimetric 
validation status of measures used in HD to assess aspects related with QoL, and to make 
recommendations on their use following standardized criteria. We included both patient-
centered measures (patient Health-related (HR) Quality of Life (QoL) measures) and 
caregiver-centered measures (caregiver QoL measures). After conducting a systematic 
literature search, we included 12 measures of patient HRQoL and 2 measures of caregiver 
QoL. Regarding patient-centered measures, the Medical Outcomes Study 36-Item Short-Form 
Health Survey is “recommended” as a generic assessment of HRQoL in patients with HD. 
The 12-Item Short Form Health Survey, the Sickness Impact Profile, the 12-item World 
Health Organization Disability Assessment Schedule, and the Huntington's Disease Health-
Related Quality of Life questionnaire are “suggested”. No caregiver-centered QoL measure 
obtained a “recommended” status.  The Alzheimer’s Carer’s Quality of Life Inventory and the 
Huntington's Disease Quality of Life Battery for Carers are “suggested”. Recognizing that the 
assessment of patient HRQoL can be challenging in HD, as patients may lack insight and 
there is insufficient clinimetric testing of these scales, the committee concluded that further 
validation of currently available HRQoL measures should be undertaken, namely, those HD-
specific HRQoL measures that have recently been reported and used. 
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INTRODUCTION 
Huntington’s disease (HD) is a complex neurodegenerative disorder in which motor, 
cognitive and behavioral manifestations have a significant impact on health-related quality of 
life (HRQoL) of patients. The concept of HRQoL has been developed to express the aspects 
of overall quality of life (QoL) that can be clearly shown to be related to health, be that 
physical or mental.
1
 The World Health Organization (WHO) defines health as "a state of 
complete physical, mental, and social well-being not merely the absence of disease.”
2
 The 
WHO lists the following functioning domains as being part of HRQoL: physical, social, 
relational, and emotional well-being.
1
 Although, the term “QoL” is often used 
interchangeably with the term “HRQoL”, QoL is a much broader multidimensional concept. 
The WHO defines QoL as “the individuals’ perception of their position in life in the context 
of the culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns”.
1
 Another important concept that is often used in QoL literature is 
health status (HS). HS is defined as the perceived health in descriptive terms of physical and 
mental symptoms, disability, and social dysfunction related to the health condition.
3
 It is 
different from HRQoL in that it lacks judgments and reactions.
3
 As stated in a similar review 
for HRQoL measures used in Parkinson’s disease, it is reasonable to consider HS as a relevant 
factor for HRQoL, which is a component of QoL in general.
4
   
HRQoL is an important patient-reported outcome that constitutes a core assessment of the 
efficacy of clinical interventions in HD, as these interventions ideally seek to not only 
improve patients’ symptoms, but ultimately to improve patient QoL. It is therefore important 
that valid and reliable measures are available that can be used in HD. In addition to measures 
centered on patients (patient-centered HRQoL measures), the sub-committee the authors 
decided we also to included measures centered on caregivers and their own QoL (caregiver-
centered QoL measures), recognizing that HD impacts the “global” QoL of caregivers and a 
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potential change in QoL is not necessarily related to health and may include other aspects of 
life.
5, 6
  
 
METHODS 
Organization and critique process 
The Committee on Rating Scales Development of the MDS appointed a team of 10 members 
(sub-committee) to review clinical measures used in HD to assess HRQoL measures; these 
members included specialists in HD, and an expert in scale development and clinimetrics 
(A.M.D.). Two sub-committee members evaluated each measure. If a sub-committee member 
was involved in the development of a measure, he/she was not involved in its review. Data 
were extracted into a proforma provided by the MDS and adapted for the purpose of the 
current review. The assessment of the measure included the description of the measure, its 
availability, context of use, and reported clinimetric properties in patients with HD.  All sub-
committee members jointly assessed the completed r views of the measures. Any unresolved 
issues and limitations of the critiqued measures were identified for discussion and reporting. 
The final recommendations were based on consensus among the sub-committee members and 
the liaison member of the Committee on Rating Scales Development of the MDS (E.C.). 
 
Selection of measures 
The methodology for this review was modeled on a previously used methodology.
7
 A 
literature search was performed using Medline on PubMed, Web of Science, EMBASE, and 
Psychinfo. The keywords used in the search included: “Huntington*” OR “Westphal variant” 
OR “juvenile Huntington*”, and the terms “scale” OR “questionnaire” OR “index” OR 
“measure” as well as the keywords: ”Quality of life”, “QoL”, “health-related quality of life”, 
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“HRQoL”, “health status”. For each identified clinical measure, a search was conducted for 
the terms “Huntington's disease,” or “Huntington disease” or “Huntington*” and the name of 
the measure.  Manuscripts published before October 17, 2016 were retrieved using the above 
search strategy and thoroughly screened by the chair of the sub-committee (T.A.M.) to 
ascertain which measure had been used in each study.  
 
Inclusion/exclusion for review 
Measures used at least nce in HD populations (patients at risk, presymptomatic gene carriers, 
and symptomatic HD patients) were included. Measures were excluded from review if they 
were not available in English, were only mentioned in reviews but not used in an original 
study, were created for a specific study without any information about their structure or use, 
or if the full-paper was not available (e.g., abstract format only). In terms of construct of 
measures, the sub-committee decided to include all measures proposed by developers to 
capture HRQoL, QoL or HS that have been used in HD studies.  
 
Criteria for rating  
We followed the Classification System for Scale Recommendation used by the MDS that uses 
three criteria: (1) Use in HD populations; (2) Use in HD by groups other than the original 
developers and data on its use are available; (3) The available clinimetric/psychometric data 
in HD support the goals of measurement of severity (e.g., evaluation of reliability, construct 
validity, and score discrimination across levels of symptom severity). Specific to this review, 
while HrQoL is not a symptom per se, it reflects the multidimensional construct of the 
impact of a disease/condition on QoL. The ability to differentiate across different levels 
of severity still stands as fundamental for a valid assessment of HrQoL (or caregiver 
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QoL) in observational studies or clinical trials. (for further details, see Table 1.) 
RESULTS  
Identified Measures and Their Use in Clinical Research 
A total of 19 clinical measures that have been used in HD research studies were identified. 
One of these measures was excluded after abstract review due to inadequacy of measure 
construct (see supplementary material). The remaining 18 clinical measures were included for 
an in-depth review. Four measures were excluded because: 1) their sole use in HD was in case 
series without any clinimetric data available (the Manchester Assessment of Quality of Life, 
the Fatigue Impact scale), 2) it was created solely for a single study (a Non-Standardized QoL 
question), and 3) the proposed construct was inadequate for the current review (the Caregiver 
Burden Inventory). We grouped the 14 remaining measures into patient-centered HRQoL 
measures (n=12) and caregiver-centered QoL measures (n=2).  
For patient-centered HRQoL measures, only The Medical Outcomes Study 36-Item Short-
Form Health Survey was (SF-36) received a classification of “recommended” as a generic 
assessment of health status in manifest HD (severity). The 12-Item Short Form Health Survey 
(SF-12), the Sickness Impact Profile (SIP), the Huntington’s Disease Health-Related Quality 
of Life Questionnaire (HDQoL), and the 12-item World Health Organization Disability 
Assessment Schedule (WHODAS 2.0), were classified as “suggested” (see supplementary 
material for overview of all assessments classified as “suggested with caveats” or “listed”). 
For caregiver-centered QoL measures, no measure was “recommended” for any of the 
purposes considered in this review. The Alzheimer’s Carer’s Quality of Life Inventory 
(AQLI), and the Huntington's Disease Quality of Life Battery for Carers (HD-QoL-C) were 
classified as “suggested” (see supplementary material for overview of all assessments 
classified as “suggested with caveats” or “listed”). 
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Patient-centered HRQoL rating scales  
 
Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) 
The SF-36 is an easy-to-administer self-reported set of generic measures of patient health 
status developed by the RAND Corporation as part of the Medical Outcomes Study (MOS). 
The SF-36 assesses eight functional dimensions: physical functioning, physical role 
limitations, mental health, emotional role limitations, social functioning, energy/vitality, pain, 
and general health perceptions, which can be summarized into two scores (physical and 
mental) and a global utility index.8 The SF-36 has been widely used in HD
9-12
, and the vast 
majority of the data was collected using version 1 of SF-36. The most current SF-36 
version 2 has less ambiguous wording, improved layout, change in response choices for 
some items, and increased cross-cultural validity.  
 
Internal consistency has been shown for the SF-36 subscales, and domain and component 
scores (Cronbach’s alpha ≥0.80).
9-12
 The test-retest reliability coefficients, as measured by 
Intra-Class Coefficient (ICC), have been reported to be > 0.70 for all domains, apart from the 
“emotional role” domain (ICC= 0.63). The Mental Health summary score has been shown to 
correlate only with the Beck Depression Inventory (BDI), while the Physical Health summary 
score of the SF-36 correlates with the BDI and a patient’s self-rated and clinician’s rating of 
patients’ level of functioning/independence level, but no factor analysis has been conducted 
for the SF-36 in this population. The SF-36 (total score, Vitality score, and Mental 
Component Score) have been shown to be sensitive to change in manifest HD clinical 
trials
9
 
11, 13
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Recommendation: The SF-36 is “recommended” as a generic assessment of health status in 
manifest HD (severity). The physical summary score seems to have better construct validity 
in HD. It is not known if the more recent SF-36 Version 2 performs equally well in HD as the 
SF-36 Version 1.  
 
Medical Outcomes Study 12-Item Short-Form Health Survey (SF-12) 
The SF-12 is a 12-item shorter version of the SF-36. It covers the same functional dimensions 
as the SF-36 but includes fewer items, and thus, is quicker to administer (2 minutes vs. 8-12 
minutes for the SF-36).
14
 It has been used less extensively in HD than the SF-36.
8
 It is 
currently being used in Enroll-HD but no data have been reported.
15
 Various degrees of 
convergent validity have been reported between the SF-12 Physical and Mental Health 
components, and the components of the HD-PRO-Triad (SF-12 physical component, 
Pearson’s correlations: motor, -0.79; cognition -0.77; emotion/behavioral dyscontrol -0.47; 
total score -0.76. SF-12 mental component, cognition -0.61; motor -0.51; total score -0.61), 
and emotion/behavioral dyscontrol (Pearson’s correlation: -0.53, all p<0.05).
16
 The SF-12 
Physical component, but not the Mental Health component, has been shown to be sensitive to 
change following multidisciplinary rehabilitation.
17
 
Recommendation: The SF-12 is “suggested” as a generic assessment of health status in 
manifest HD (severity), as it lacks test-retest reliability data and internal consistency data. 
 
Sickness Impact Profile (SIP) 136 items 
The SIP is a generic measure of self-reported health status,
18
 consisting of 136 items covering 
12 categories grouped into two subscales (physical and psychosocial). Scores are presented as 
a percentage of maximal dysfunction ranging from 0 to 100; a higher score indicates a higher 
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level of dysfunction. The SIP can take up to 30 minutes to complete. The SIP has been used in 
two studies in manifest HD,
19, 20
 and a modified version using only 3 of the 12 categories was 
used in trial for cognition in HD.
21
 Internal consistency has been reported to be high 
(Cronbach’s alpha > 0.80),
19
 as has test-retest reliability (ICC> 0.70) for scores of subscales 
and all categories, aside from the “emotional behavior” (ICC=0.49) and “work” (ICC=0.68) 
categories.
19
 The SIP total score has been shown to correlate with both the patient’s self-rated 
(Spearman’s correlation: -0.69) and clinician’s rating (Spearman’s correlation: -0.64) of 
patients’ level of functioning/independence (all p< 0.01), with the BDI (Spearman’s 
correlation: 0.47, p<0.01), and with the Unified Huntington’s Disease Rating Scale – Total 
Motor Score (UHDRS-TMS) (Spearman’s correlation: 0.32, p<0.05). The Psychosocial 
subscale has been shown to correlate with both the patient’s self-rated and the clinician’s 
rating of patients’ level of functioning/independence, while the Physical subscale has been 
shown to correlate with both the BDI and the UHDRS-TMS, in addition to both the patient’s 
self-rated and the clinician’s rating of patients’ level of functioning/independence. 
19
 In a 
head-to-head comparison with the SF-36, the SIP was shown to have a worse clinimetric 
performance with less robust construct validity and test–retest reliability. In addition, motor 
symptoms appeared to influence some strictly non-motor dimensions of the SIP.
19
  
Recommendation: The SIP is “suggested” for assessing health status in manifest HD 
(severity). There are limited clinimetric data on its use in HD, and it performs worse than the 
SF-36 in a head-to-head comparison.  
 
World Health Organization Disability Assessment Schedule (WHODAS) 2.0 (12-item) 
The WHODAS 2.0 was developed by the World Health Organization (WHO) and includes six 
domains of functioning. Nevertheless, the WHODAS 2.0 is often considered a generic 
function-related measure of health status and consequently it was decided by consensus to 
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include it in this review and not in the review of measures for assessment of functional ability 
in HD. The WHODAS 2.0 can be administered as interviewer-, self-, and proxy-administered 
forms. The WHODAS 2.0 12-item version, which is reviewed here, takes 5 minutes to 
complete and covers 6 domains: cognition, mobility, self-care, getting along, life activities, 
and participation. The WHODAS 2.0 12-item has been used in three studies including both 
pre-manifest and manifest HD.
22-24
 Internal consistency has been shown with a Cronbach's 
alpha of 0.94 (95% CI: 0.93 - 0.94).
22
 Moderate convergent validity has been reported 
between the WHODAS 2.0 and other health-related quality of life assessments such as the 
RAND-12 (Pearson correlations ranging from - 0.76 to -0.41), and the EuroQol Five-
dimension questionnaire (EQ-5D; Pearson correlations ranging from = - 0.65 and -0.49).
22
 
The scores in the WHODAS 2.0 differ significantly across the disease spectrum from the pre-
manifest stage to late HD.
22
 In pre-manifest HD, cross-sectional differences between low-, 
mid- and high- disease burden groups have been reported.
23
 In pre-manifest HD, only the 
companion-rated (proxy) version of the WHODAS 2.0 has been shown to be sensitive to 
change over a period of three years.
23
 
Recommendation: The WHODAS 2.0 12-item is “suggested” for assessing health status in 
HD (severity), as it lacks important clinimetric development in HD, namely, for test-retest 
reliability testing and requires more robust construct validity.  
 
The Huntington's Disease Health-Related Quality of Life Questionnaire (HDQoL) 
The HDQoL is a patient-reported questionnaire that was specifically developed for use in HD 
to assess HRQoL.
25
 The HDQoL covers three main domains: “primary physical and 
cognitive”, “primary emotions and self”, and “primary services”.
25
 It takes about 22 minutes 
to complete. The HDQoL has been used in one study by authors
26
other than the group
25, 27
 
who originally developed it. The internal consistency of each of the domains has been shown 
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to vary: “primary services” (Cronbach’s alpha = 0.76), “primary emotions and self” 
(Cronbach’s alpha = 0.89), and “primary physical and cognitive” (Cronbach’s alpha = 0.96). 
Test-retest reliability has been reported, but as this was evaluated with Cronbach’s alpha it 
does not provide a true adequate measure of concordance.
25
 Item ceiling effects range from 
12.5% to 50%.25 
Recommendation: The HDQoL is “suggested” for assessment of HRQoL in HD (severity), 
as there are limited clinimetric data, namely related with construct validity and test-retest 
reliability. 
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Caregiver-centered QoL measures 
 
The Alzheimer’s Carer’s Quality of Life Inventory (ACQLI) 
The ACQLI was developed to assess caregiver QoL in Alzheimer’s disease (AD).
28
 It is a 
quick (<5 minutes) questionnaire that consists of 30 items to which the caregiver answers true 
or not true; 1 point is given for each true answer, giving a possible total score of 30. The 
ACQLI has been used in a single HD study, in a head-to-head comparison with the HD-QoL-
C. The ACQLI 
29
 showed excellent internal consistency (Cronbach alpha = 0.95).
29
  
Recommendation: The ACQLI is “suggested” for assessing QoL for HD caregivers 
(severity), as its use in HD is limited to a single study in HD and clinimetric data in HD are 
limited to internal consistency.  
 
Huntington's Disease Quality of Life Battery for Carers (HD-QoL-C) 
The HD-QoL-C is a HD-specific, multi-dimensional measure for family or caregivers of 
patients with HD. It is based upon the domains and facets of the Comprehensive Quality of 
Life Scale for Adults (ComQol-A5).
30
 Two versions are available: a long-form that consists of 
34 items which incorporate measures on “practical aspects of caregiving” (n=9), “satisfaction 
with life” (n=8) and “feelings about living with HD” (n=17), and a short-form that consists of 
20 items (3 items on “satisfaction of life”, and 17 items on “feelings about living with HD”).
29
 
The HD-QoL-C has been used in four studies in HD.
9, 29, 31, 32
 Internal consistency of the long-
form has been shown for the domains “satisfaction with life” (Cronbach’s alpha = 0.91) and 
“feelings about living with HD” (Cronbach’s alpha = 0.84), but not for the domain “practical 
aspects of caregiving” (Cronbach’s alpha = 0.62).
29
 For the short-form, internal consistency 
has been shown (“satisfaction with life”, 0.92; total score, 0.88).
29
 A low correlation has been 
reported between the HD-QoL-C and the WHO Quality of Life Short Form (WHO-QoL 
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BREF),
32
 and the Huntington Quality of Life Instrument (H-QoL-I; correlations 0.22 to 0.28, 
all p<0.01). 
31
 
Recommendation: The HD-QoL-C is “suggested” for assessing QoL for HD caregivers 
(severity). It warrants further additional clinimetric development, namely in terms of 
validity, reliability and data reproducibility by other groups.  
 
Discussion 
 
We report here the results of an in-depth review of 12 measures used in HD studies to 
evaluate patient-centered HRQoL. The SF-36 is the only measure that can be classified as 
“recommended” to measure patient’s HRQoL in terms of severity. None of the HRQoL 
measures developed specifically for HD have undergone sufficient clinimetric development to 
warrant a similar classification level. There were no HRQoL measures recommended to 
measure change of intensity severity over time. Regarding patient-centered HRQoL 
measures, the sub-committee identified the following topics that warrant consideration when 
developing these types of measures:  
1) The inherent subjective nature of self-reporting HRQoL warrants a special comment 
as HD patients often lack insight regarding the presence or severity of their symptoms. 
Along the same lines, the progressive cognitive impairment experienced by HD 
patients is likely to introduce additional difficulties in ensuring the reliability of 
patient-reported HRQoL in HD, namely, at later stages. Proxy reporting was rarely 
included in the measures reviewed here and could be further assessed and considered 
as a strategy to mitigate the above-mentioned limitations of patient-reported outcomes 
in HD. 
2) As HD is a rare disease, studies often require a multi-center multi-national design that 
raises the need for validation of HRQoL and QoL measures across different cultures. 
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In this review, there were no data available on a formal cross-cultural validation for 
any of the included measures when applied to HD populations. Consequently, cross-
cultural validation should be implemented in future development programs of HRQoL 
measures in HD.  
3) We discussed the need for a generic measure vs. a disease-specific measure. Given the 
complexity of the clinical presentation of HD, it is likely that a generic scale will not 
capture all the disease features that significantly impact on the HRQoL of these 
patients, and thus a disease-specific measure may be better positioned to capture 
HRQoL in HD in a valid manner. On the other hand, although disease-specific 
measures are usually more sensitive, generic measures are able to capture global 
aspects of health that may be overlooked by the specific scales. A disease-specific 
measure that incorporates items likely found in generic measures is possibly the best 
approach.  
 
The committee also looked at caregiver-centered QoL measures. We recognize that these 
measures have their own issues. In this review, we included two caregiver-centered QoL 
measures, one developed in Alzheimer’s disease and another specifically developed for HD. 
Although caregivers play a role in caring for patients with a wide range of neurodegenerative 
disorders, and there are many features in common between caring for such patients and caring 
for a progressively dependent patient, there are limited data available to determine if 
similarities across neurodegenerative disorders are sufficient to warrant a general QoL scale 
or whether caregiver QoL needs to be disease-specific. A caregiver-centered measure that 
considers both disease-specific items and more generic items would likely be the best 
approach. 
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In the current review we identified several measures that were ‘listed’. In many cases, these 
measures have had limited evaluation of their measurement properties in HD. Still, other 
recently developed HD-specific measures are in the initial stages of comprehensive 
measurement property testing, these include the HDQLIFE, the HDQoL, or HD-PRO-
TRIAD.  Importantly, some of these newer measures incorporate patient stakeholders in their 
development, a contribution deemed essential by regulatory agencies such as the US Food and 
Drug Administration (FDA) for patient-reported outcomes supporting labeling claims.
33
 
Further testing of the measurement properties and uptake of these measures by groups other 
than the developers is required to determine their real value in evaluating HRQoL in HD 
patients. The committee concluded that the evaluation of the measurement properties of the 
currently available measures that are included in this review, namely those developed 
specifically for HD, is warranted. This should be a priority for HD researchers, considering 
for example the increasing importance of patient-reported outcomes in the development of 
novel therapies and their subsequent approval by regulatory authorities. 
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EXCLUDED SCALES:  
 
• Inadequate construct (n=1) 
• Family members' perception of community health care services (CHCS) for persons with HD1 
• The Caregiver Burden Inventory2 
 
 
• Developed solely for a single study (n=1) 
• A Non-Standardized QoL question3 
 
 
• Used in a single HD study and no clinimetric data available (n=2) 
• The Manchester Assessment of Quality of Life4 
• The Fatigue Impact scale5 
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Short-Form 36 Health Survey (SF-36) 
I. Scale description 
Are there several versions of the scale?  
Yes. 
SF-36 v1 and SF-36 v2.  
RAND 36 includes the same items as SF-36 (from the medical outcome study).1, 2 
SF-36 v2 has improved wording and instructions, which are less ambiguous.  
Layout of questions and answers is also improved; there is also increased comparability 
(translations and cultural adaptations), five-level response choices in place of dichotomous 
choices for the seven items in the Role-Physical and Role-Emotional scales, elimination of a 
response option from the items of the Mental Health and Vitality scales.  
If you replied YES, which was been assessed? 
SF36 v1, as most of the clinimetric evaluation was done using this scale. 
 
NOTE: SF-36 v2 was used in Registry 3 and is currently used in Enroll-HD.3 
Scale construct/ overall structure 
The SF-36 a survey of health status developed for use in the Medical Outcomes Study, a multi-
year study of patients with chronic conditions. 
 
The SF-36 has 36 items that cover 8 functional dimensions: (physical functioning, physical 
role limitations, mental health, emotional role limitations, social functioning, energy/vitality, 
pain, and general health perceptions).  
 
The SF-36 comprises two summary measures: physical component summary and the mental 
component summary. 
 
Several different scoring methods are available, scoring procedures of the MOS SF-36 are 
available from the International Resource Center for Health Care Assessment.1, 4 
http://www.rand.org/health/surveys_tools/mos/36-item-short-form/scoring.html 
a. Question items    
Items of presence of symptom/sign? Yes. 
Items of severity of symptom/sign? Yes. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Discrete (2, 3, 5 or 6). 
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c. Is the scale easy to score? 
 
Approx. time to score patient  8-12 minutes.5, 6 
d. Raters   
Patient, caregiver, or clinician Patient self-report. 
If clinician-rated, is training for application required? Not applicable. 
e. Access to scale   
Copyright or public domain? 
The SF-36 v1 is freely available from the RAND corporation (www.rand.org) 
NOTE: the SF-36 v2 is licensed and has more materials for instruction and evaluation (Optum: 
www.optum.com) 
How can the scale be obtained (address or website)? http://www.rand.org/health/surveys_tools/mos/36-item-short-form.html 
Has the scale been published in other languages? Yes. 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction 
Yes. 
 
The SF-36 was adapted from instruments completed by patients participating in the MOS.7  
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes. 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
No. 
Does it score current state or is it based on the 
patient/caregiver recall? 
Current state. 
What is the time frame (e.g. “during the past week”)?   
Mostly past 4 weeks. Some items in comparison with a year ago. 
http://www.rand.org/health/surveys_tools/mos/36-item-short-form/survey-instrument.html  
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Assess health status level (severity). 
Is there a cut-off score? (for HD, for  non-HD) 
There is no cut-off score in HD. 
 
Mental health and mental component summary score cut offs have been established for 
diagnosing depression in various populations.8, 9 
Page 70 of 146
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
d. Acceptability   
Is the length of the scale appropriate? Yes (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Yes, but they are not complete (judgment of the task force). 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Advanced HD patients will not be able to fill in the questionnaire by themselves (judgment of 
the task force).  
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
No. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable. 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  Yes. 
a. Reliability 
 
Assessed – not assessed Assessed in HD. 
Internal consistency 
Manifest HD, n=48. 
Cronbach’s alpha ≥0.80.3  
 
Test-retest reliability  
Manifest HD, n=48. 
ICC > 0.70 for the SF-36 dimensions and aggregate scales, with exception of the “emotional 
role limitation” subscale for patients (ICC=0.64).3  
Inter-rater reliability  — 
b. Validity in HD   
Assessed vs. not assessed Assessed in HD.3 
Criterion validity (any comparison with gold-standard) 
There is no gold standard. 
 
Note: In a head-to-head comparison with the SIP, performed better, with more robust construct 
validity and test-retest reliability; in addition, motor symptoms appeared to influence some 
strictly non-motor dimensions of the SIP.3 
Construct validity    
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Factor analysis 
Not assessed in HD. 
 
Assessed in non-HD populations during initial scale development.7 
Convergent validity 
Manifest HD, n=48. Correlation of SF-36 v1 components with BDI, UHDRS Total Motor 
Section, clinician’s self-rated score on the patient’s level of functioning and patient’s self-rated 
score on the patient’s level of functioning 
1. BDI: correlation with all components and summary scores of the SF-36 (except for 
physical functioning). Correlation coefficient range: 0.35 – 0.66, all p< 0.05. 
NOTE: higher correlations with non-physical components. 3 
2. UHDRS Total Motor Section: correlation with only Mental health component 
(Spearman’s correlation, 0.27) and Physical functioning (Spearman’s correlation, 
0.54, all p< 0.05) 3 
3. Clinician’s self-rated score on the patient’s level of functioning:  correlation with 
the physical functioning component (Spearman’s 0.70), physical role limitations 
(Spearman’s 0.45), energy/vitality (Spearman’s 0.35), general health perceptions 
(Spearman’s 0.46), physical summary (Spearman’s 0.59) and the SF-36 Utility 
Index (Spearman’s 0.54; all p< 0.05). 3 
4. Patient’s self-rated score on their level of functioning: correlation with the physical 
functioning (Spearman’s 0.64), physical role limitations (Spearman’s 0.42), 
general health perceptions (Spearman’s 0.44), physical summary (Spearman’s 
0.57) and the SF-36 Utility Index (Spearman’s 0.51) all significantly correlate with 
the (p< 0.05).3 
5. Telephone Interview of Cognitive Status: correlation with the physical functioning 
(Spearman’s 0.51), physical summary (Spearman’s 0.36) and SF-36 Utility Index 
(Spearman’s 0.32, all p<0.05). 
Manifest HD, n=70.
10
 
Physical summary score correlated with UHDRS-TMS (r= -0.41), BDI (r= -0.51), verbal 
fluency (r= 0.21), symbol digit modality test (r= 0.29), and UHDRS-TFC (r= -0.51, all 
p<0.05). 
Mental summary score correlated only with BDI (r= -0.72) and UHDRS-TFC (r=0.42) 
 
 
Manifest HD, n=80 
11
 
SF-36 mental summary correlated with depressive mood (Hamilton Rating Scale), but not with 
motor or cognition scales.  
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Manifest HD, n=252, app. 2 year of symptom duration 
12
 
H-QoL-I vs. SF-36:  
• SF-36 physical summary vs.: H-QoL-I motor functioning (r=0.74), psychology 
(r=0.59), socializing (r=0.55) and total (r=0.75, all p<0.01). 
• SF-36 mental summary vs.: H-QoL-I motor functioning (0.44), psychology (0.58) and 
socializing (0.52) and total (r=0.65, all p<0.01). 
 
Non-HD populations: (please see Brazier 1992)13 
 
Divergent validity - 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
There is some good data to support this measure.  It has a reasonable psychometric data and it 
performed batter than the SIP (judgment of the task force) 
Generalizability   
Shown to be valid at any stage of HD? Yes, used in several HD populations.14 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Questionable use as it is a patient self-report (judgment of the task force).  
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
The SF-36 has been shown to be sensitive to change following multidisciplinary rehabilitation 
in early-to-mid HD.15 
No change reported in quality of life as measured with the SF-36 following a structured home-
based exercise program in mid-stage HD.16 
 
The SF-36 Vitality score significantly improved in HD (stages 2-3) following a 4 week 
treatment trial with (-)-OSU6162.17 
The SF-36 Mental Component Score significantly improved following a 12-week community-
based exercise program (p<0.05).18 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects Not assessed in HD. 
Score distributions 
Manifest HD, n=70.
10
 
• Physical functioning: 66.80 (34.11) 
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• Role functioning—physical: 50.60 (44.58) 
• Bodily pain: 84.45 (22.97) 
• General health: 57.43 (23.69) 
• Vitality: 59.21 (23.69) 
• Social functioning: 61.75 (22.13) 
• Role functioning emotional: 57.62 (48.13) 
• Mental health: 71.70 (19.58) 
• Physical summary score: 26.43 (39.11) 
• Mental summary score: 19.35 (41.60) 
 
NOTE: The SF-36 (Version 2) total score has been shown to differentiate between HD and 
controls (p<0.0001), between pre-manifest HD and HD (p=0.0004), and between HD stage 2 
and HD stage 1 (p <0.0001), but not between pre-manifest HD vs. controls (p=0.21).14 
IV. Overall impression 
Advantages  
Generic instrument.  
This is a generic instrument, which enables comparison between diseases.  
Relevant, depending on question at hand.  
Disadvantages  Does not differentiate emotion and mental aspects 
V. Recommendation Recommended as a generic assessment of health status in HD (severity) 
 
 
 
 
 
References 
 
1. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med 
Care 1992;30:473-83. 
2. RAND. In. 
3. Ho AK, Robbins AO, Walters SJ, Kaptoge S, Sahakian BJ, Barker RA. Health-related quality of life in Huntington's disease: a 
comparison of two generic instruments, SF-36 and SIP. Mov Disord 2004;19:1341-8. 
4. Hays RD, Shapiro MF. An overview of generic health-related quality of life measures for HIV research. Qual Life Res 1992;1:91-7. 
Page 74 of 146
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
5. Hayes V, Morris J, Wolfe C, Morgan M. The SF-36 health survey questionnaire: is it suitable for use with older adults? Age Ageing 
1995;24:120-5. 
6. Pickard AS, Johnson JA, Penn A, Lau F, Noseworthy T. Replicability of SF-36 summary scores by the SF-12 in stroke patients. Stroke 
1999;30:1213-7. 
7. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of 
validity in measuring physical and mental health constructs. Med Care 1993;31:247-63. 
8. Silveira E, Taft C, Sundh V, Waern M, Palsson S, Steen B. Performance of the SF-36 health survey in screening for depressive and 
anxiety disorders in an elderly female Swedish population. Qual Life Res 2005;14:1263-74. 
9. Walsh TL, Homa K, Hanscom B, Lurie J, Sepulveda MG, Abdu W. Screening for depressive symptoms in patients with chronic spinal 
pain using the SF-36 Health Survey. Spine J 2006;6:316-20. 
10. Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality of life in Huntington's disease: Which factors matter 
most? Mov Disord 2009;24:574-8. 
11. Brugger F, Hepperger C, Hametner EM, Holl AK, Painold A, Schusterschitz C, et al. [Predictors of mental and physical quality of life in 
Huntington's disease]. Nervenarzt 2015;86:167-73. 
12. Clay E, De Nicola A, Dorey J, Squitieri F, Aballea S, Martino T, et al. Validation of the first quality-of-life measurement for patients with 
Huntington's disease: the Huntington Quality of Life Instrument. Int Clin Psychopharmacol 2012;27:208-14. 
13. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new 
outcome measure for primary care. BMJ 1992;305:160-4. 
14. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington's disease 
in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801. 
15. Thompson JA, Cruickshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA, et al. The effects of multidisciplinary rehabilitation in 
patients with early-to-middle-stage Huntington's disease: a pilot study. Eur J Neurol 2013;20:1325-9. 
16. Khalil H, Quinn L, van Deursen R, Dawes H, Playle R, Rosser A, et al. What effect does a structured home-based exercise programme 
have on people with Huntington's disease? A randomized, controlled pilot study. Clinical rehabilitation 2013;27:646-58. 
17. Kloberg A, Constantinescu R, Nilsson MK, Carlsson ML, Carlsson A, Wahlström J, et al. Tolerability and efficacy of the monoaminergic 
stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study. Acta neuropsychiatrica 2014;26:298-306. 
18. Busse M, Quinn L, Debono K, Jones K, Collett J, Playle R, et al. A randomized feasibility study of a 12-week community-based exercise 
program for people with Huntington's disease. J Neurol Phys Ther 2013;37:149-58. 
 
 
 
Page 75 of 146
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 76 of 146
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 77 of 146
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 78 of 146
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Short-Form 12 Health Survey (SF-12) 
I. Scale description 
Are there several versions of the scale? Yes. 
SF-12 v1, SF-12 v2.1 
If you replied YES, which was been assessed? Both versions. 
Scale construct/ overall structure The SF-12 is based in the SF-36, but has fewer items (12 vs. 36). 
 
As the SF-36, the SF-12 is a patient-reported survey of patient health that covers 8 functional 
dimensions: physical functioning, physical role limitations, mental health, emotional role 
limitations, social functioning, energy/vitality, pain, and general health perceptions. 
a. Question items  
Items of presence of symptom/sign? Yes. 
Items of severity of symptom/sign? Yes. 
b. Response scale  
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Discrete steps (3 or 5). 
c. Is the scale easy to score?  
Approx. time to score patient SF-12, < 2 minutes.2 
d. Raters  
Patient, caregiver, or clinician Patient self-report. 
If clinician-rated, is training for application required? Not applicable. 
e. Access to scale  
Copyright or public domain? Copyright. 
How can the scale be obtained (address or website)? QualityMetric @ https://www.optum.com/campaign/ls/outcomes-survey-request.html 
Has the scale been published in other languages? Yes. 
II. Scale properties 
a. Content validity  
Any process for item generation and/or reduction Yes. 
The SF-12 represents an item reduction effort from SF-36. 
 
The following criteria were followed for item reduction:3 
1) Could be scored to explain at least 90% of the variance in SF-36 physical and 
mental health summary measures; 
2) Would reproduce the average scores for the summary measures and eight-scale 
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profile with a high degree of comparability; 
3) Could be printed on one to two pages of a self-administered questionnaire or 
administered by an interviewer in less than 2 minutes, on average. 
b. Face validity  
Do the items of the scale cover different components of 
the specific domain? 
Yes (judgment of the task force). 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
No (judgment of the task force). 
Does it score current state or is it based on the 
patient/caregiver recall? 
Current state and patient recall. 
What is the time frame (e.g. “during the past week”)? Past 4 weeks, but some items refer to one year ago. 
c. Use  
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Assess health status level (severity). 
Is there a cut-off score? (for HD, for  non-HD) No. 
d. Acceptability  
Is the length of the scale appropriate? Yes (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Yes (judgment of the task force). 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Not suitable in advanced stages (judgment of the task force). 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
No. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable. 
  
III. Clinimetric/psychometric properties  
Are there  clini- or psychometric properties in HD ? Yes. 
a. Reliability  
Assessed – not assessed Assessed in HD. 
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Internal consistency Not assessed in HD. 
Test-retest reliability Not assessed in HD. 
Inter-rater reliability Manifest HD, n=132; HD caregivers, n=40 
SF-12 Physical component: HD individuals self-reported vs. caregiver-reported scores: ICC = 
0.94 (CI 95%: 0.88, 0.97).4 
SF-12 Mental health component: HD individuals self-reported vs. caregiver-reported scores: 
ICC = 0.83 (95% CI: 0.68, 0.91).4 
b. Validity in HD  
Assessed vs. not assessed Partially in the development of new scales. 
Criterion validity (any comparison with gold-standard) - 
Construct validity  
Factor analysis Not assessed in HD. 
Convergent validity Manifest HD, n=152.5 
SF-12v2 physical component: Correlation coefficients: Physical and Cognitive (0.8) of the 
Primary scales, and the Physical and 
Functional (0.8) of the Six Specific Scales of the HDQoL. 
SF-12v2 mental component: Correlation coefficients: emotions and self (0.8) of the Primary 
scales, and Mood state (0.7), Self and Vitality (0.7) of the Six Specific Scales of the HDQoL. 
NOTE: P values not reported. 
 
Manifest HD, n=132,
4
 Correlation between the SF-12v2 components of HD-PRO-Triad: 
SF-12 physical component correlated with motor (Pearson’s correlation: -0.79), cognition 
(Pearson’s correlation: -0.77), total score (Pearson’s correlation: -0.76) and emotion/behavioral 
dyscontrol (Pearson’s correlation: (-0.47). 
SF-12 mental component correlated with cognition (Pearson’s correlation: -0.61), total score 
(Pearson’s correlation: -0.61), motor (Pearson’s correlation: -0.51), and emotion/behavioral 
dyscontrol (Pearson’s correlation: -0.53). 
NOTE: p<0.05.4 
Divergent validity Manifest HD, n=152.5 
SF-12v2 physical component: Correlation coefficients: emotions and self (0.4), of the Primary 
scales, and the Mood state (0.3), Self and Vitality (0.5) of the Six Specific Scales of the 
HDQoL. 
SF-12v2 mental component: Correlation coefficients: Physical and Cognitive (0.5) of the 
Primary scales, and Physical and Functional (0.4) of the Six Specific Scales of the HDQoL, 
NOTE: P values not reported. 
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Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
Good evidence of construct validity. No reliability data. 
Generalizability  
Shown to be valid at any stage of HD? No. 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
No. Questionable as self-report by patient 
Responsiveness (detect change over time in the construct) 
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
The SF-12 physical component, but not the mental component, has been shown to be sensitive 
to change following a multidisciplinary rehabilitation.6 
Interpretability 
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects Not reported. 
Score distributions Manifest HD, n=105.
7
 
SF-12v2 Physical Component Score: 41.52 ± 12.78 
SF-12v2 Mental Component Score: 39.95 ± 11.50 
 
Manifest HD, n=132 4 
SF-12v2 Physical Component Score: 37.7 ± 10.8 
SF-12v2 Mental Component Score: 41.3  ± 10.5 
IV. Overall impression 
Advantages This is a generic instrument, which enables comparison between diseases. 
Does not differentiate emotional aspects. Good for physical health related items. Relevant, 
depending on question at hand. Heavily used in HD (Registry, Enroll-HD). 
Relevant depending on research question, purpose of use. 
Disadvantages Does not differentiate emotion, mental 
Physical component is acceptable. 
V. Recommendation Suggested as a generic assessment of health status in manifest HD (severity) 
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Sickness Impact Profile (SIP) 
I. Scale description 
Are there several versions of the scale?  
Yes.  
Original of 136 items. 
In 1994, a shorter version of the SIP, the SIP-68, was created and evaluated; this version 
contains 68 items in six areas of activity: somatic autonomy; mobility control; psychological 
autonomy and communication; social behavior; emotional stability; and mobility range.1 
Cubo et al. used a modified version that included only 3 out of 12 categories of the SIP.2 
If you replied YES, which was been assessed? The original, 136 items 
Scale construct/ overall structure 
It is a generic measure of perceived health status.3  
 
It consists of 136 items; 2 subscales physical and psychosocial; 12 categories (sleep and rest, 
eating, work, home management, recreation and pastimes, ambulation, mobility, body care and 
movement, social interaction, alertness behavior, emotional behavior, communication). 
 
An overall SIP percent score may be obtained by summing the scale values of all items 
endorsed in the entire SIP, dividing that sum by the sum of the values of all the items in the 
SIP and multiplying the obtained quotient by 100.  Scores for each category are calculated in a 
like manner. 
 
Scores on the SIP are presented as a percentages of maximal dysfunction ranging from 0 to 
100, higher scores on the SIP indicate a higher level of dysfunction: SIP scores < 6 indicate no 
impairment, scores between 6 and 10 are indicative of mild impairment, scores between 15 and 
20 indicate moderate to severe impairment, and scores > 20 are indicative of severe illness-
related impairment.3 
a. Question items    
Items of presence of symptom/sign? Yes. 
Items of severity of symptom/sign? No. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
The SIP is a checklist, whereby items that apply on a given day are ticked. 
c. Is the scale easy to score? 
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Approx. time to score patient  30 minutes (judgment of the task force). 
d. Raters   
Patient, caregiver, or clinician Patient self-report or interview. 
If clinician-rated, is training for application required? No. 
e. Access to scale   
Copyright or public domain? Copyright. 
How can the scale be obtained (address or website)? E-mail Mapi Research Trust @ trust@mapi.fr  
Has the scale been published in other languages? 
None currently authorized by the copyright holder. Guidelines for translation are available 
through the Medical Outcomes Trust or through Johns Hopkins University. (Judgment of the 
task force). 
II. Scale properties 
a. Content validity  
Any process for item generation and/or reduction 
Initial work began in 1972 with the development of procedures to collect and evaluate 
statements describing sickness-related behavioral dysfunction from patients, individuals caring 
for patients, and apparently healthy health care professionals. 
These statements were subjected to standard grouping and sorting techniques yielding 312 
unique items (reduced to 136 in the final form) each describing a sickness-related behavioral 
change.  
 
The 312 items were grouped into areas of activity or categories and then included in a 
prototype Sickness Impact Profile. This questionnaire, together with its applications, reliability 
testing, validation and revisions was the subject of the field trials to be described. 
 
The strategy chosen for developing, assessing and revising the SIP was based on 
methodological principles that emphasized the evaluation of reliability and validity in a variety 
of settings, the determination of the relationship of the SIP to other measures currently in use 
and the evaluation of its unique contribution as an outcome measure of health status. This 
strategy was operationalized and implemented through a series of field trials, each designed to 
address specific issues in the developmental process. The sequential properties of the overall 
research design were particularly valuable.3  
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes. 
Is the scale heavily weighted towards one aspect of the - 
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domain it measures and which components of the domain 
are not covered? 
Does it score current state or is it based on the 
patient/caregiver recall? 
Current time. 
What is the time frame (e.g. “during the past week”)?   “Today” 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Assess perceived health status (severity). 
Is there a cut-off score? (for HD, for  non-HD) No 
d. Acceptability   
Is the length of the scale appropriate? Too long (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Not enough data to determine. 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Not enough data to determine. 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
No. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable. 
III. Clinimetric/psychometric properties  
 
Are there clini- or psychometric properties in HD ?  Yes.4 
a. Reliability 
 
Assessed – not assessed Assessed in HD. 
Internal consistency 
Manifest HD, n=48. 4 
Cronbach’s alpha: > 0.80 at time 1 and time 2 (exact value not provided).  
Test-retest reliability  
Manifest HD, n=48. 4 
All ICC's above 0.7 (including total score), except emotional behavior and work. 
Inter-rater reliability  - 
b. Validity in HD   
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Assessed vs. not assessed Assessed in HD. 
Overall impression: good – not good  Very limited data for an impression to be given. 
Criterion validity (any comparison with gold-standard)  - 
Construct validity    
Factor analysis Not assessed in HD. 
Convergent validity 
Manifest HD, n=48. Correlation of SIP components with BDI, UHDRS Total Motor Section, 
clinician’s self-rated score on the patient’s level of functioning and patient’s self-rated score 
on the patient’s level of functioning.4 
 
Physical dimension: correlation with BDI (r=0.29), UHDRS Total Motor Section (r=0.42), 
Clinician’s self-rated score on the patient’s level of functioning (r=-0.72), Patient’s self-rated 
score on their level of functioning (r=-0.72), and Telephone Interview of Cognitive Status (r=-
0.29). 
 
Psychosocial dimension: correlation with Clinician’s self-rated score on the patient’s level of 
functioning (r=-0.40), and Patient’s self-rated score on their level of functioning (r=-0.51), and 
BDI (r= 0.60). 
 
Total SIP score: correlation with BDI (r=0.47), UHDRS Total Motor Section (r=0.32), 
Clinician’s self-rated score on the patient’s level of functioning (r=-0.64), Patient’s self-rated 
score on their level of functioning (r=-0.69), and Telephone Interview of Cognitive Status (r=-
0.33) 
NOTE: all p<0.05. 
Divergent validity See above in “Convergent validity” 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
Spearman’s correlations support convergent/divergent validity but very variable.  
Too long. (Judgment of the task force). 
Generalizability   
Shown to be valid at any stage of HD? Only assessed in manifest HD. 4, 5 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Yes. (Judgment of the task force). 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
Unknown.  
NOTE: Cubo et al. used a modified version, reported no change but the trial was negative.2 
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Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No 
Floor and ceiling effects Not reported. 
Score distributions Not reported. References in HD only show graphs with scores. 
IV. Overall impression 
Advantages  Some psychometric data in HD. 
Disadvantages  
Too long. 
Performed worse in a head-to-head comparison with SF-36. 
V. Recommendation Suggested for assessing perceived health status in manifest HD (severity) 
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12-item World Health Organization Disability Assessment Schedule (WHODAS) 2.0  
I. Scale description 
Are there several versions of the scale?  
Yes. 
There are 12-item and 36-item versions available. 
The 36-item version can be scored simply or via an item response theory (IRT)-based scoring 
algorithm. 
The WHODAS is available as interviewer-, self-, and proxy-administered forms. 
http://www.who.int/classifications/icf/more_whodas/en/ 
If you replied YES, which was been assessed? WHODAS 2.0, 12-item version (more frequently used in HD).  
Scale construct/ overall structure 
The WHODAS II assesses health status, disability, and functioning, linked to concepts from 
the International Classification of Functioning, Disability and Health (ICF) framework. 
 
For the 12-item version, there are 2 items in six areas of day-to-day functioning: 
1. Cognition 
2. Mobility  
3. Self-care  
4. Getting along  
5. Life activities  
6. Participation    
 
Total score computed as the sum of the 12 items, with higher scores indicating worse 
functioning. 
a. Question items    
Items of presence of symptom/sign? Yes.  
Items of severity of symptom/sign? Yes. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Five response categories for each item (none=1; mild=2; moderate=3; severe=4; 
extreme/cannot do=5).    
http://www.who.int/classifications/icf/more_whodas/en/ 
c. Is the scale easy to score? 
 
Approx. time to score patient  
5 minutes. 
http://www.who.int/classifications/icf/more_whodas/en/ 
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d. Raters   
Patient, caregiver, or clinician 
VARIABLE: 
Self-administration of a paper-and-pencil version. 
Interview administered in person or over the telephone.  
Proxy i.e. to obtain a third-party view of functioning such as; family members, caretakers or 
other observers. 
If clinician-rated, is training for application required?  
e. Access to scale   
Copyright or public domain? Public domain. 
How can the scale be obtained (address or website)? http://www.who.int/classifications/icf/more_whodas/en/ 
Has the scale been published in other languages? Yes.  
II. Scale properties 
a. Content validity  
Any process for item generation and/or reduction — 
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
It covers multiple domains: examines activity limitations and restrictions for six different 
tasks: (1) understanding and communication; (2) self-care; (3) mobility (getting around); (4) 
interpersonal relationships (getting along with others); (5) work and household roles (life 
activities); and (6) community and civic roles (participation); 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
1-2 items domain so relatively well balanced (judgment of the task force). 
Does it score current state or is it based on the 
patient/caregiver recall? 
Patient/caregiver recall. 
What is the time frame (e.g. “during the past week”)?   The past 30 days. 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Assess health status (severity). 
Is there a cut-off score? (for HD, for non-HD) No. 
d. Acceptability   
Is the length of the scale appropriate? Yes (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force) 
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Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
The questions are somewhat general. (Judgment of the task force). 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Limited information on applicability in very late stage HD, and also in the context of cognitive 
impairment. (Judgment of the task force). 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
No. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable. 
III. Clinimetric/psychometric properties   
Are there  clini- or psychometric properties in HD ?  Yes.1, 2 
a. Reliability  
Assessed – not assessed Assessed in HD 
Internal consistency 
Prodromal and/or manifest HD (n=477) 1 
a) Overall Cronbach's alpha = 0.94 (95% CI: 0.93-0.94).  
b) For the six subdomains, Cronbach’s alpha was 0.90 for self-care (95% CI:  0.88–0.91), 
0.89 for mobility (95% CI:  0.87–0.91), 0.83 for life activities (95% CI:  0.80–0.86), 
0.82 for cognition (95% CI:  0.78–0.85), 0.74 for getting along (95% CI:  0.69–0.78), 
and 0.74 for participation (95% CI:  0.69–0.78).  
Test-retest reliability  - 
Inter-rater reliability  - 
b. Validity in HD   
Assessed vs. not assessed Assessed in HD. 
Criterion validity (any comparison with gold-standard)  - 
Construct validity    
Factor analysis 
Prodromal and/or manifest HD (n=477)
1
 
6 factor structure replicated in HD sample, CFI = 0.99, TLI = 0.99, and RMSEA = 0.02. 
Convergent validity 
Prodromal and/or manifest HD (n=477)
1
 
Moderate to significant correlations with other general measures of HRQOL (i.e., EQ5D and 
RAND-12); correlations ranged from -0.41 to -0.76 (RAND-12 Physical [-0.76], EQ-5D index 
[-0.65], EQ-5D health scale [-0.49], and the RAND-12 Mental [-0.41], all p<0.0001.1 
Divergent validity - 
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References 
 
1. Carlozzi NE, Kratz AL, Downing NR, Goodnight S, Miner JA, Migliore N, et al. Validity of the 12-item World Health Organization 
Disability Assessment Schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD). Qual Life Res 2015;24:1963-71. 
Overall impression: good – not good (based on references 
preferably, judgment of the task force can be stated) 
 
Generalizability   
Shown to be valid at any stage of HD? 
Prodromal and/or manifest HD (n=477)
1
 
Analysis showed that late HD participants have poorer scores than early HD, who had lower 
scores than pre-manifest HD participants.  
Pre-manifest HD, n=726; companions, n= 630
2, 3
 
In pre-manifest HD, cross-sectional differences between low-, mid- and high- disease burden 
groups have been reported.  
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
No. (judgment of the task force) 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
No.  
NOTE: in Kim et al, Pre-manifest HD, n=726; companions, n= 630, data suggests sensitivity 
over a three-year duration only for the proxy-rated version.2, 3 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
Not reported. 
Floor and ceiling effects 
Prodromal and/or manifest HD (n=477)
1
 
Ceiling effect (19.5%).1 
Score distributions - 
IV. Overall impression 
Advantages  
The WHODAS 12-item version is brief and has validation data in both pre-manifest and 
manifest HD. 
Disadvantages  Limited uptake. 
V. Recommendation Suggested for assessing health status in HD (severity) 
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Huntington’s Disease Health-related Quality of Life questionnaire (HDQoL) 
I. Scale description 
Are there several versions of the scale?  No.  
If you replied YES, which was been assessed? 
Not applicable. 
 
 
Scale construct/ overall structure 
HDQoL is a 40-item scale with three primary subscales (Primary Physical and Cognitive 
(PPC), (ii) Primary Emotions and Self (PES), and (iii) Primary Services (PSR) and Six 
Specific Scales (Cognitive, Hopes and Worries, Services, Physical and 
Functional, Mood State, Self and Vitality). 1 
a. Question items    
Items of presence of symptom/sign? Yes 
Items of severity of symptom/sign? No 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Discrete:  Never, Very rarely, Infrequently, Sometimes, Often, Most of the time, All Of the 
time 
c. Is the scale easy to score? 
 
Approx. time to score patient  22 minutes (administration time).1 
d. Raters   
Patient, caregiver, or clinician 
Patient  
NOTE: the patient can invite a proxy to complete a form based on how the proxy felt the 
patient would answer. 1 Agreement between patient-Proxy forms agreement was substantial to 
excellent for the Summary Scale score of the HDQoL, and also for most of its Specific Scales. 
2There was a tendency for proxies to over-estimate internal emotional aspects of patients’ 
health-related quality of life as better than patients’ own ratings, while on more external 
physical and cognitive aspects the reverse was true.3 
If clinician-rated, is training for application required? Not applicable 
e. Access to scale   
Copyright or public domain? Copyright 
How can the scale be obtained (address or website)? http://www.hdqol.info 
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Has the scale been published in other languages? 
Unknown.  
NOTE:  during development of item structure: Where necessary, these items were translated 
by two appropriately bilingual members of the European Huntington’s Disease Network 
Quality of Life Working Group and/or their associates.1 
 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction 
In Hocaoglu 2012  et al: 1 
1) Item generation from qualitative interviews 
Semi-structured interviews were conducted with the full spectrum of people living with HD, to 
form a pool of items, which were then examined in a larger sample prior to data-driven item 
reduction.  
2) Item selection and questionnaire refinement 
 Feedback on these initial items was sought from a wider pool of people living with HD to aid 
data-driven item 
selection.  Items with low importance scores, high omission rates or ambiguous content were 
eliminated.    
3) Pre-testing of HDQoL 
b. Face validity  
 
Do the items of the scale cover different components of 
the specific domain? 
Yes  
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
Apparently no. 
Does it score current state or is it based on the 
patient/caregiver recall? 
Patient recall 
What is the time frame (e.g. “during the past week”)?   “Past month” 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
degree of HrQoL (Severity). 
Is there a cut-off score? (for HD, for  non-HD) No. 
d. Acceptability  NOTE: Unable to review items, but presumably yes. 
Is the length of the scale appropriate? It is very long, which suggests that the items are overly complex.1 
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Are there ambiguities in instructions to patient/rater (as 
applicable)? 
Minimal instructions. 
Are there ambiguities in rating anchors? Somehow. Difficult to differentiate between response options for frequency of symptoms. 
Are the questions appropriate for use in an HD 
population? 
Yes 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Yes.1 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
Yes.1 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Yes.4 
III. Clinimetric/psychometric properties  
 
Are there clini- or psychometric properties in HD ?  Yes. 
a. Reliability 
 
Assessed – not assessed Assessed 
Internal consistency 
Pre-manifest, at risk and manifest HD, n=152
1
 
Cronbach’s alpha ≥0.7 for three primary scales and Sum score: “Primary physical and 
cognitive” = 0.96, “Primary Emotions and Self” =0.89; “Primary Services” =0.76 
Test-retest reliability  
Pre-manifest, at risk and manifest HD, n=152
1 
Sum score=0.7.  
All sub scales ≥0.7. p<0.0001.1   
NOTE: Cronbach was used – not appropriate measure to report test-retest reliability 
Inter-rater reliability  Not applicable. 
b. Validity in HD   
Assessed vs. not assessed Assessed in HD. 
Criterion validity (any comparison with gold-standard) No. 
Construct validity  
 
Factor analysis 
Pre-manifest, at risk and manifest HD, n=152
1
 
Three-factor (Primary scales) solution was found: (i) Primary Physical and Cognitive (PPC), 
(ii) Primary Emotions and Self (PES), and (iii) Primary Services (PSR).1 6 factor (specific 
scales) solution was also presented: (i) Specific Cognitive (SCG), (ii) Specific Hopes and 
Worries (SHW), (iii) Specific Services (SSR), (iv) Specific Physical and Functional (SPF), (v) 
Specific Mood State (SMS), and (vi) Specific Self and Vitality (SSV).  
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Submitted to RASCH analysis. Retained items did not show differential item functioning for 
gender, although differential item functioning analyses cannot be run for this few participants 
(generally 200 people per group are required, and therefore this analysis is not deemed 
accurate).  
Convergent validity 
Pre-manifest, at risk and manifest HD, n=152
1
 
Correlation between the sum score and the SF-12 (physical: 0.6 mental:0.7).  
Correlation between the sum score and the EQ5D (range for subscales: -0.4 to -0.7). 
 
Comment: Method unknown. P values not given  
Divergent validity -  
Known groups validity 
Ratings become progressively poorer across the three groups.3 
Comment: data for the moderate HD group are not as expected—data for early and advanced 
HD are as expected.1 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
In general, there are some positives, but it is long, the psychometrics are adequate to good. 
This measure has not gained traction, likely due to the length and some of the less impressive 
psychometric properties (judgment of the task force). 
Generalizability   
Shown to be valid at any stage of HD? Not evaluated. 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Not evaluated. 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
Mid-stage HD, n=30 
In a Randomized Controlled Feasibility Trial for Task-Specific Training in HD: at 8 weeks: -
3.7 (95% CI: -9.0, 1.6), at 12 weeks: 3.9 (95% CI:  -4.1, 11.9), all n.s.  
Comment: methodology to calculate effect size is not clear – “Effect sizes are calculated from 
the adjusted treatment effect”.4 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No 
Floor and ceiling effects 
Pre-manifest, at risk and manifest HD, n=152
1
 
Floor effects < 12.5 for all scales and sum score (good). 
Ceiling effect: sum score =16.4 (< 10 excellent and < 20 acceptable). Item ceiling effects 
ranged from 12.5 to 50; the following scale exceeds what is acceptable: Physical/cognitive 
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(30.9), services (50.0), cognitive (27), services (50), physical and functional (36.2)1 
Score distributions 
Pre-manifest, at risk and manifest HD, n=152
1 
Skewness is acceptable.  
IV. Overall impression 
Advantages  Psychometric data is generally adequate to good 
Disadvantages  
Long administration time (judgment of the task force) 
Unclear if it is sensitive to change over time.  
Only one group, other than the developers have used this measure.  
User access is restricted.  
V. Recommendation Suggested for assessment of health-related QoL in HD (severity) 
 
 
 
References 
 
1. Hocaoglu MB, Gaffan EA, Ho AK. The Huntington's Disease health-related Quality of Life questionnaire (HDQoL): a disease-specific 
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3. Hocaoglu MB, Gaffan EA, Ho AK. Health-related quality of life in Huntington's disease patients: a comparison of proxy assessment and 
patient self-rating using the disease-specific Huntington's disease health-related quality of life questionnaire (HDQoL). J Neurol 2012;259:1793-
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EQ-5D 
I. Scale description 
Are there several versions of the scale?  
Yes. 
EQ-5D-3L, EQ-5D-5L and EQ-5D-Y (EQ-5D Youth version), an EQ-5D-3L self-complete 
version for children and adolescents aged 8-15. 
http://www.euroqol.org/eq-5d-products.html 
If you replied YES, which was been assessed? 
EQ-5D-3L, EQ-5D-5L  
 
Scale construct/ overall structure 
The EQ-5D is a standardized non-disease-specific instrument for describing and evaluating 
health-related quality of life.1 Nevertheless, the EQ-5D asks about health state to respondents. 
http://www.euroqol.org/eq-5d-products/how-to-obtain-eq-5d.html 
  
The EQ-5D consists of a 5-question multi-attribute questionnaire and a visual analogue self-
rating scale.  
The 5 questions are titled in the following domains: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression. 
 
The EQ5D Health Scale scores range from 0 (low health) to 100 (highest level of health), 
while the EQ5D Index Value scores range from 0 (low health) to 1 (highest level of health). 
a. Question items    
Items of presence of symptom/sign? Yes. 
Items of severity of symptom/sign? Yes. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Discrete steps (3L version - no problems/some or moderate problems/extreme problems; 5L - 
no problems/slight problems/moderate problems/severe problems/extreme problems) and a 
VAS. 
c. Is the scale easy to score? 
 
Approx. time to score patient  5 minutes. 
d. Raters   
Patient, caregiver, or clinician Patient. 
If clinician-rated, is training for application required? Not applicable. 
e. Access to scale   
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Copyright or public domain? 
Copyright. 
NOTE: If non-commercial parties intend to use EQ-5D for research purposes, no license fee is 
charged.  
http://www.euroqol.org/eq-5d-products/how-to-obtain-eq-5d.html 
How can the scale be obtained (address or website)? 
EuroQol Research Foundation.  
http://www.euroqol.org/eq-5d-products/how-to-obtain-eq-5d.html 
Has the scale been published in other languages? Yes. 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction -- 
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes. 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
No. 
Does it score current state or is it based on the 
patient/caregiver recall? 
Current state. 
What is the time frame (e.g. “during the past week”)?   Today. 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
To measure severity. 
Is there a cut-off score? (for HD, for  non-HD) No. 
d. Acceptability   
Is the length of the scale appropriate? Yes (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Yes, partially (judgment of the task force). 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
No (judgment of the task force). 
e. Has this scale been specifically developed for use in HD No. 
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(yes/no)? 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable. 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  
Only minimal clinimetric testing.  
The EQ-5D has been used as a comparator in validation studies, and as a composite in new 
scales (H-QoL, I HD-PRO-TRIAD). 
a. Reliability 
 
Assessed – not assessed Not assessed in HD. 
Internal consistency Not assessed in HD. 
Test-retest reliability  Not assessed in HD.  
Inter-rater reliability  Not assessed in HD. 
b. Validity in HD   
Assessed vs. not assessed Only used as a comparator. 
Criterion validity (any comparison with gold-standard)  Not assessed in HD. 
Construct validity    
Factor analysis Not assessed in HD. 
Convergent validity 
Pre-manifest, at risk and manifest HD, n=152.
2
 
Correlation between the EQ5D Index Score and the HDQoL sum score: 0.8. 
 
Prodromal and/or manifest HD, n=477.
3
 
Moderate to significant correlations with WHODAS 2.0: EQ-5D index [-0.65], EQ-5D health 
scale [-0.49], all p<0.0001.  
Divergent validity 
 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
Limited information for a substantive impression. 
Generalizability   
Shown to be valid at any stage of HD? Used in several studies. 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Likely not (judgment of the task force). 
Responsiveness (detect change over time in the construct)  
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Demonstrated to be sensitive to change (change over time 
or to treatment)? 
Not in HD. 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects 
Prodromal and/or manifest HD, n=477.3 
23.9 % for the EQ5D index scale; and 8.9 % for the EQ5D health scale).  
Score distributions 
Pre-manifest, at risk and manifest HD, n=105.
4
 
EQ-5D Index Score - 0.56 ± 0.35 
 
Prodromal HD, n=190, 0.89 ± 0.12.3 
Early HD, n=196, 0.80 ± 0.14.3 
Late HD, n=89, 0.71 ± 0.16. 3 
IV. Overall impression 
Advantages  
Widely used, but limited use in HD.  
Simple, generic (comparison with other neurological diseases). 
Disadvantages  
Ceiling effects. 
Limited validation in HD. 
V. Recommendation Suggested with caveats 
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RAND-12 Health Status Inventory (HIS) 
I. Scale description 
Are there several versions of the scale?  Yes. 12-, 20- and 36-item versions. 
If you replied YES, which was been assessed? The 12-item version. 
Scale construct/ overall structure 
General health status. 
The RAND 12 is based on the SF-12 which summarizes four of the Medical Outcomes Study 
36 Item Short-Form Health Survey (SF-36) eight health dimensions (physical functioning, 
role-physical, role-emotional, and mental health) using two items each. The remaining four 
health dimensions (pain, vitality, social functioning, and general health) are each represented 
by a single item.  
 
The RAND 12 comprises the same 12 items as the SF12 but uses scaling based on Item 
Response Theory.  
 
It also includes two extra items on change in physical and emotional health over the past year. 
http://www.rand.org/health/surveys_tools/mos/12-item-short-form.html 
a. Question items    
Items of presence of symptom/sign? Yes. 
Items of severity of symptom/sign? Yes. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Discrete steps, 6 for most of the items. 
c. Is the scale easy to score? 
 
Approx. time to score patient  Scoring algorithm required. 
d. Raters   
Patient, caregiver, or clinician Patient. 
If clinician-rated, is training for application required? Not applicable. 
e. Access to scale   
Copyright or public domain? Public domain. 
How can the scale be obtained (address or website)? Freely available from the principal developers e.g. Dr. Lewis Kazis at lek@bu.edu 
Has the scale been published in other languages? Yes. 
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II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction See SF12. 
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
See SF12. 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
See SF12. 
Does it score current state or is it based on the 
patient/caregiver recall? 
Mostly patient recall. 
What is the time frame (e.g. “during the past week”)?   Past 4 weeks. 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Mainly to measure severity. 
Is there a cut-off score? (for HD, for  non-HD) No. 
d. Acceptability   
Is the length of the scale appropriate? Yes (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
Yes (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
The scale is somewhat general (judgment of the task force). 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Limited information on applicability in very late stage disease and also in the context of 
cognitive impairment (judgment of the task force). 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
No. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable. 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  Yes. 
a. Reliability  
Assessed – not assessed Not assessed in HD. 
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Internal consistency - 
Test-retest reliability  - 
Inter-rater reliability  
- 
b. Validity in HD   
Assessed vs. not assessed Assessed in HD. 
Criterion validity (any comparison with gold-standard)  - 
Construct validity    
Factor analysis 
 
Convergent validity 
Prodromal and/or manifest HD, n=477  
Moderate to significant correlations with WHODAS 2.0: RAND-12 Physical [-0.76] and the 
RAND-12 Mental [-0.41], all p<0.0001.1  
Divergent validity - 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
Very limited information. 
Generalizability   
Shown to be valid at any stage of HD? 
Limited in HD.  
Physical Health composite score is poorer for late HD compared to early HD, which was lower 
than for pre-manifest HD.  
For the Mental Health composite score there were no differences between late, early and 
prodromal HD.1 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Limited information on applicability in very late stage disease and also in the context of 
cognitive impairment (judgment of the task force). 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
No. 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects 
Prodromal and/or manifest HD, n=477.
1  
No floor or ceiling effects.  
Score distributions RAND-12.1  
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Physical Health 
Prodromal HD, n=190, 53.87 ± 5.58 
Early HD, n=196, 46.88 ± 9.18 
Late HD, n=87, 38.17 ± 9.09 
Mental Health 
Prodromal HD, n=190, 49.87 ± 9.32 
Early HD, n=196, 47.60 ± 10.99 
Late HD, n=87, 49.60 ±11.42 
IV. Overall impression 
Advantages  Brief. 
Disadvantages  
Not specifically for HD.  
Mental health composite score same for all HD (pre-manifest, early and late HD). 
Very limited validation in HD. 
V. Recommendation Suggested with caveats 
 
 
 
 
References 
 
1. Carlozzi NE, Kratz AL, Downing NR, Goodnight S, Miner JA, Migliore N, et al. Validity of the 12-item World Health Organization 
Disability Assessment Schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD). Qual Life Res 2015;24:1963-71. 
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Neuro-QoL (Quality of Life in Neurological Disorders) 
I. Scale description 
Are there several versions of the scale?  
Yes, different item banks within Neuro-QoL. 
http://www.healthmeasures.net/explore-measurement-systems/neuro-qol 
If you replied YES, which was been assessed? 
In HD, a self-report version with a fixed-length short forms of the following item banks has 
been used: 1) Anxiety, 2) Depression, 3) Social Roles, 4) Lower extremity function, 5) Upper 
extremity function.1 
More recently, the item banks of the domains Stigma, Emotional and Behavioral Dyscontrol, 
Positive Affect and Well-Being, Ability to Participate in Social Roles and Activities, 
Satisfaction with Social Roles and Activities, Lower Extremity-Function/Mobility, Upper 
Extremity-Function/ADLs, Applied Cognition-Executive Functioning, Applied Cognition-
General Concerns have also been used.2 
Scale construct/ overall structure 
Neuro-QoL instruments were developed through a collaborative, multi-site research initiative 
to construct psychometrically-sound and clinically-relevant health-related quality of life 
(HRQOL) measurement tools for individuals with neurological conditions or disorders such as 
stroke, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), 
epilepsy, and muscular dystrophy (MD).  
 
Each item bank consists of 8 to 9 items. 
 
http://www.healthmeasures.net/explore-measurement-systems/neuro-qol/measure-
development-research 
a. Question items    
Items of presence of symptom/sign? Yes. 
Items of severity of symptom/sign? Yes. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Five response options. 
c. Is the scale easy to score? 
 
Approx. time to score patient  Scoring algorithm is required. 
d. Raters   
Patient, caregiver, or clinician Patient. 
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If clinician-rated, is training for application required? Not applicable. 
e. Access to scale   
Copyright or public domain? 
Copyright, but all English and Spanish version of Neuro-QoL are publicly available for use in 
one’s individual research, clinical practice, educational assessment, or other application 
without licensing or royalty fees. 
How can the scale be obtained (address or website)? 
From the NINDS. 
http://www.healthmeasures.net/explore-measurement-systems/neuro-qol 
Has the scale been published in other languages? Yes. 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction 
 
http://www.healthmeasures.net/explore-measurement-systems/neuro-qol 
 
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes (judgment of the task force)/ 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
NOTE:  by design, each measure is focused on a single aspect of HRQoL, thus they are 
intentionally developed to be unidimensional measures. 
Does it score current state or is it based on the 
patient/caregiver recall? 
Based on patient recall. 
What is the time frame (e.g. “during the past week”)?   Past 7 days. 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Measures severity. 
Is there a cut-off score? (for HD, for  non-HD) No. 
d. Acceptability   
Is the length of the scale appropriate? Yes (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Yes, but somewhat general (judgment of the task force). 
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Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Limited information on applicability in very late stage disease and also in the context of 
cognitive impairment (judgment of the task force). 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
No. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable. 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  No. 
a. Reliability  
Assessed – not assessed Not assessed in HD. 
Internal consistency - 
Test-retest reliability  - 
Inter-rater reliability  - 
b. Validity in HD   
Assessed vs. not assessed Not assessed in HD. 
Criterion validity (any comparison with gold-standard)  - 
Construct validity    
Factor analysis Not assessed in HD. 
Convergent validity 
Manifest HD, n=132.3 Correlation between the different NEURO-QOL components and total 
score of HD-PRO-Triad:  
Anxiety (Pearson’s correlation: 0.70), Depression (Pearson’s correlation: 0.71), Social Roles 
(Pearson’s correlation: 0.55), Lower extremity function (Pearson’s correlation: 0.73), Higher 
extremity function (Pearson’s correlation: 0.74). 
NOTE: p<0.05  
 
Neuro-QoL had moderate relationships with WHODAS 2.0 and EQ-5D (correlation 
coefficients  ranged: 0.34 – 0.74, p < 0.0001).2 
Divergent validity Not assessed in HD. 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
Very limited information on which to base an impression. 
Generalizability   
Shown to be valid at any stage of HD? Pre-manifest and manifest HD, n=536 
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Pre-manifest HD performed better than early-HD and late-HD, and early-HD performed better 
than late-HD. (P values not provided) 2 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Likely not (judgment of the task force). 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
No. 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects Unknown. 
Score distributions 
Manifest HD, n=132.3 
Anxiety - 57.5 (8.0). 
Depression - 54.1 (8.2). 
Social Roles - 42.2 (7.4). 
Lower extremity function - 38.3 (10.9). 
Higher extremity function - 33.0 (11.6). 
IV. Overall impression 
Advantages  Single domain short forms are brief. 
Disadvantages  
Multiple short forms might be needed and assessment is longer. 
Very limited use and validation in HD 
V. Recommendation Suggested with caveats 
 
References 
 
1. Carlozzi NE, Victorson D, Sung V, Beaumont JL, Cheng W, Gorin B, et al. HD-PRO-TRIAD Validation: A Patient-reported Instrument 
for the Symptom Triad of Huntington's Disease. Tremor Other Hyperkinet Mov (N Y) 2014;4:223. 
2. Carlozzi NE, Schilling SG, Lai JS, Paulsen JS, Hahn EA, Perlmutter JS, et al. HDQLIFE: development and assessment of health-related 
quality of life in Huntington disease (HD). Quality of Life Research 2016;25:2441-55. 
3. Carlozzi NE, Kratz AL, Downing NR, Goodnight S, Miner JA, Migliore N, et al. Validity of the 12-item World Health Organization 
Disability Assessment Schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD). Qual Life Res 2015;24:1963-71. 
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PROMIS Global Health (PROMIS) 
I. Scale description 
Are there several versions of the scale?  
Yes. 
The 10-item version.  
The 29-item version.  
http://www.healthmeasures.net/explore-measurement-systems/promis 
If you replied YES, which was been assessed? The 10-item version. 
Scale construct/ overall structure 
The PROMIS assesses global health perception, and consists of 10 items, with each item 
having 5 response options apart from pain where 10 options are presented. 
 
The 10-item PROMIS Global Health instrument yields two summary scores — Physical 
Health and Mental Health. 
 
http://www.healthmeasures.net/explore-measurement-systems/promis 
a. Question items    
Items of presence of symptom/sign? Yes. 
Items of severity of symptom/sign? Yes. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Discrete step:  5 (Variable anchors), except for pain where there are 10 (from “No pain” to 
“Worst Imaginable Pain”). 
c. Is the scale easy to score? 
 
Approx. time to score patient  Scoring algorithm is required. 
d. Raters   
Patient, caregiver, or clinician Patient. 
If clinician-rated, is training for application required? Not applicable 
e. Access to scale   
Copyright or public domain? 
Copyright. 
NOTE: publicly available for use without licensing or royalty fees for individual research or 
individual clinical use, meaning solely for user’s research, clinical, educational, or other 
application.  
http://www.healthmeasures.net/explore-measurement-systems/promis/obtain-administer-
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measures 
How can the scale be obtained (address or website)? 
From PROMIS. 
http://www.healthmeasures.net/explore-measurement-systems/promis/obtain-administer-
measures 
Has the scale been published in other languages? 
Danish, Dutch, English, French, German, Italian, Portuguese, Simplified Chinese (Mandarin), 
Spanish 
http://www.healthmeasures.net/search-view-measures?task=Search.search 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction  
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes (judgment of the task force). 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
NOTE:  by design, each measure is focused on a single aspect of HRQoL, and are thus 
intentionally developed to be unidimensional measures. 
Does it score current state or is it based on the 
patient/caregiver recall? 
Patient recall. 
What is the time frame (e.g. “during the past week”)?   Past 7 days (three last questions) or “in general”. 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Measure severity. 
Is there a cut-off score? (for HD, for  non-HD) 
 
d. Acceptability   
Is the length of the scale appropriate? Yes (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Yes, although they do not specifically address HD issues (judgment of the task force). 
Is the scale applicable across HD disease stages?                                          
Are there HD stages in which the scale is not applicable? 
Limited information on applicability in very late stage disease and also in the context of 
cognitive impairment1 (judgment of the task force). 
e. Has this scale been specifically developed for use in HD No. 
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(yes/no)? 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable.  
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  Some. 
a. Reliability 
 
Assessed – not assessed Not assessed in HD. 
Internal consistency - 
Test-retest reliability  - 
Inter-rater reliability  
- 
b. Validity in HD   
Assessed vs. not assessed Assessed in HD. 
Criterion validity (any comparison with gold-standard) Not assessed in HD. 
Construct validity    
Factor analysis 
 
Convergent validity 
Manifest HD, n=132.1 
Correlation between the different PROMIS Global Physical measures and different score of the 
HD-PRO-Triad:  
PROMIS Global Physical Health vs. HD-PRO-TRIAD Total (0.82), Cognition (0.83), Motor 
Function (0.80) and Emotional/Behavioral Dyscontrol (0.57).  
PROMIS Global Mental Health vs. HD-PRO-TRIAD Total (0.77), Cognition (0.72), Motor 
Function (0.62) and Emotional/Behavioral Dyscontrol (0.73).1 
Divergent validity - 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
Very limited information. 
Generalizability   
Shown to be valid at any stage of HD? No. 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Limited information on applicability in very late stage disease and also in the context of 
cognitive impairment. 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time No. 
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or to treatment)? 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects 
 
Score distributions 
Manifest HD, n=132.1  
PROMIS Global Physical Health 42.6 (9.7) 
PROMIS Global Mental Health 39.0 (10.5) 
IV. Overall impression 
Advantages  
 
Disadvantages  Online study and questionnaire completion. 
V. Recommendation Suggested with caveats 
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Huntington Disease Health-Related Quality of Life (HDQLIFE) 
I. Scale description 
Are there several versions of the scale?  No. 
If you replied YES, which was been assessed? Not applicable. 
Scale construct/ overall structure 
HDQLIFE is a patient-reported outcome measurement system that was developed to capture 
both the generic and more unique aspects of HRQOL in HD.1 
It includes 12 validated Neuro-QoL/PROMIS measures in HD, as well as five new HD-
specific measures, including speech and swallowing dysfunction,2 chorea,3 and end of life 
issues including concerns with death and dying, and meaning and purpose.4 
a. Question items    
Items of presence of symptom/sign?  
Items of severity of symptom/sign? Yes.2-4 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
The HDQLIFE uses computer adaptive tests (CATs) where each individual item is selected 
based on the response to the previous item The HDQLIFE can also use Static Short forms 
(which are 6-items) depending on the administrator’s preference.1  
c. Is the scale easy to score?  
Approx. time to score patient  Administration of each HDQLIFE measure is < 1 minute.1 
d. Raters   
Patient, caregiver, or clinician Clinician. 
If clinician-rated, is training for application required? Unknown. 
e. Access to scale   
Copyright or public domain? Public domain. 
How can the scale be obtained (address or website)? www.assessmentcenter.net, free of charge. 
Has the scale been published in other languages? - 
II. Scale properties 
a. Content validity  
Any process for item generation and/or reduction 
HDQLIFE validates 12 PROMIS/NEURO-QoL domains to capture generic, relevant aspects of 
health-related QoL in patients with HD.1 
1. Item development:  
a. The relevant domains, subdomains, and items to assess HRQOL in HD were 
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identified through literature review and qualitative focus groups including at-
risk, pre-manifest, manifest HD individuals, non-clinical caregivers, and HD 
clinicians.5 While several PROMIS/Neuro-QoL measures were identified as 
relevant in HD, a number of HD-specific HRQOL issues were found not to be 
captured by these measures.1, 5 
b. Preliminary item pools were created to examine chorea, speech and 
swallowing difficulties, and end of life issues. Each item pool went through 
several iterations following expert review, cognitive debriefing interviews 
with people with HD, literacy and translatability review: the initial HDQLIFE 
Chorea item pool consisted of 141 items, later reduced to 64; the Speech and 
Swallowing pool initially consisted of 102 items, later revised to 47 items; the 
End of Life Concerns item pool initially consisted of 69 later reduced to 45 
items.1 
2. Quantitative study. 
3. All items were field tested in 536 patients with pre- and manifest HD. 
4. Computer adaptive tests (CATs) were developed for each of the domains: 
a. Exploratory and confirmatory factor analyses were used to identify 
unidimensional item pools (speech difficulties (27 items) and swallowing 
difficulties (16 items)2, and item response theory was used to calibrate the 
final measures. 
b. Items were calibrated separately for the two item pools resulting in measures 
that can be administered as computer adaptive tests and/or 6-item static short 
forms. 
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes. 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
- 
Does it score current state or is it based on the 
patient/caregiver recall? 
Patient recall. 
What is the time frame (e.g. “during the past week”)?   Past 7 days.2-4 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
To measure severity.2-4 
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Is there a cut-off score? (for HD, for  non-HD) No. 
d. Acceptability   
Is the length of the scale appropriate? Yes. 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Yes. 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Yes. 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
Yes. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
No. 
III. Clinimetric/psychometric properties   
Are there  clini- or psychometric properties in HD ?  Yes. 
a. Reliability  
Assessed – not assessed Assessed in HD. 
Internal consistency 
Pre-manifest and manifest HD, n=536 
Chorea scale, Cronbach’s alpha 0.98, and all item-total correlations were > 0.7.3. 
Meaning and purpose, Cronbach’s alpha 0.84. item-total correlations > 0.4.4 
Death and dying scale, Cronbach’s alpha 0.94. All item-total correlations >0.4.4  
Speech Difficulties, Cronbach’s alpha 0.98 and all item-total correlations >0.4. 
Test-retest reliability  Unknown. 
Inter-rater reliability  Not applicable. 
b. Validity in HD   
Assessed vs. not assessed Assessed. 
Criterion validity (any comparison with gold-standard)  - 
Construct validity    
Factor analysis 
Exploratory and confirmatory factor analyses were used to identify unidimensional item pools, 
which were analyzed separately. Once unidimensional item sets were identified, an IRT graded 
response model was implemented. 
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Chorea: five factors were originally identified, and 40 items were retained for confirmatory 
factor analyses which revealed 6 items to have residual correlations, these were removed 
leaving 34 items; comparative fit index (CFI) = 0.98; TLI=0.98; root mean square error of 
approximation (RMSEA)=0.07, all r2>0.03.  
Meaning and purpose, reduced from 14 to 7 items. CFI = 0.99, TLI = 0.98, RMSEA = 0.11, 
all r2>0.03.4 
Death and dying, reduced from 16 items to 13. CFI = 0.97, TLI = 0.96, RMSEA = 0.15, all 
r2>0.03.4 
EFA and CFA identified two separate unidimensional sets of items:  
Speech difficulties (27 items) and Swallowing difficulties (16 items), both of which were 
developed further into 6-item short-forms and CATS. For Speech difficulties (Factor 1 in EFA 
results), acceptable fit indices were found in CFA results: CFI = 0.98, TLI = 0.98, RMSEA = 
0.09, all r2>0.3. 
Swallowing Difficulties (Factor 2 in EFA results), acceptable fit indices were found in CFA 
results: 
CFI = 0.98, TLI = 0.98, RMSEA = 0.11, all r2>0.3. 
Convergent validity 
Significant positive correlation between HDQLIFE Chorea and the UHDRS TMS (r = 0.64, 
p<0.0001).3 
Divergent validity - 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
 
Generalizability   
Shown to be valid at any stage of HD? Yes. 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Unknown. 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
Not assessed. 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No 
Floor and ceiling effects - 
Score distributions - 
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IV. Overall impression 
Advantages  
HDQLIFE includes new HD-specific items as well as generic items from PROMIS and Neuro-
QoL, which enable comparisons across different medical populations. 
Disadvantages  Requires further clinimetric development and use by other groups than developers. 
V. Recommendation 
Listed 
NOTE: Only used by one group and further clinimetric testing is required. 
 
References 
 
1. Carlozzi NE, Schilling SG, Lai JS, Paulsen JS, Hahn EA, Perlmutter JS, et al. HDQLIFE: development and assessment of health-related 
quality of life in Huntington disease (HD). Quality of Life Research 2016;25:2441-55. 
2. Carlozzi NE, Schilling SG, Lai JS, Perlmutter JS, Nance MA, Waljee JF, et al. HDQLIFE: the development of two new computer 
adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties. Quality of Life Research 2016;25:2417-27. 
3. Carlozzi NE, Downing NR, Schilling SG, Lai JS, Goodnight SM, Miner JA, et al. The development of a new computer adaptive test to 
evaluate chorea in Huntington disease: HDQLIFE Chorea. Quality of Life Research 2016;25:2429-39. 
4. Carlozzi NE, Downing NR, McCormack MK, Schilling SG, Perlmutter JS, Hahn EA, et al. New measures to capture end of life concerns 
in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement 
system). Quality of Life Research 2016;25:2403-15. 
5. Carlozzi NE, Tulsky DS. Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J 
Health Psychol 2013;18:212-25. 
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WHO-Quality of Life-BREF (WHOQOL-BREF) 
I. Scale description 
Are there several versions of the scale?  No. 
If you replied YES, which was been assessed? Not applicable. 
Scale construct/ overall structure 
Generic quality of life instrument developed by the World Health Organization (WHO).  
This is a shorter version with broad representations of the WHOQOL100.  
It consists of 26 items scored on a five-point Likert scale (from 1 = very dissatisfied to 5 = very 
satisfied).1 It includes items for physical health, psychological, social relationships and 
environment. The WHOQOL-BREF is a cross-cultural assessment of well-being.  
a. Question items    
Items of presence of symptom/sign? 
 
Items of severity of symptom/sign? Yes. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Likert scale items. Scoring instructions provided in manual 
http://www.who.int/mental_health/media/en/76.pdf 
c. Is the scale easy to score? 
 
Approx. time to score patient   
d. Raters   
Patient, caregiver, or clinician Patient self-report. 
If clinician-rated, is training for application required? 
 
e. Access to scale   
Copyright or public domain? Copyright. 
How can the scale be obtained (address or website)? World Health Organization. WHOQOL@who.int 
Has the scale been published in other languages? Yes.1 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction 
WHOQOL-100 was developed through the collaboration of 15 international sites in their own 
language.1 Pooled data from the WHOQOL-100 was used to select items for the WHOQOL-
BREF, resulting in four domains of QoL: physical, psychological, social and environment.1  
b. Face validity    
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Do the items of the scale cover different components of 
the specific domain? 
Includes items for physical health, psychological, social relationships and environment. 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
Only 3 items for domain 3 (social relationships). The other domains have 6, 7, & 8 items. 
Unbalanced (judgment of the task force). 
Does it score current state or is it based on the 
patient/caregiver recall? 
Based on patient-recall. 
What is the time frame (e.g. “during the past week”)?   
A time frame of two weeks is indicated in the assessment.  
It is recognized that different time frames may be necessary for particular uses of the 
instrument in subsequent stages of work. For example, in the assessment of QoL in chronic 
conditions, such as arthritis, a longer time frame such as four weeks may be preferable. 
Furthermore, the perception of time is different within different cultural settings and therefore 
changing the time scale may be appropriate (judgment of the task force). 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Assess well-being. 
Is there a cut-off score? (for HD, for  non-HD) Not in HD. 
d. Acceptability   
Is the length of the scale appropriate? A little long (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Yes (judgment of the task force). 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Unknown in HD. 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
No. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable. 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  No. 
a. Reliability 
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Assessed – not assessed Not assessed in HD. 
Internal consistency 
Non-HD populations: 
Cronbach’s alpha for the total population, >0.7).1 
Cronbach’s alpha for domains 1, 2 and 4 i.e. physical health=0.82, psychological=0.81, 
environment=0.80, social relationships=0.68.1 
Test-retest reliability  Not assessed in HD. 
Inter-rater reliability  Not assessed in HD. 
b. Validity in HD   
Assessed vs. not assessed Not assessed in HD. 
Criterion validity (any comparison with gold-standard)  - 
Construct validity    
Factor analysis 
Not assessed in HD. 
 
NOTE: The WHOQOL-100 was based on six theoretical domains that were reorganized into 
four domains during the development of the WHOQOL-BREF. Analysis of the total 
population data showed four factors (eigenvalues >1.0) that explained 53% of the variance in 
the data.1 
Convergent validity 
Not assessed in HD. 
 
NOTE: Construct validity was partly assessed by correlating the domain scores with each 
general item: overall assessment of QoL was most strongly associated with the psychological 
(standardized beta=0.290) and environment domains (standardized beta=0.252), and the 
overall assessment of health with the physical domain (standardized beta=0.428).1 
Divergent validity 
Not assessed in HD. 
 
NOTE: t-tests of domain scores for illness vs. well samples: 
Physical=39.2, psychological=19.9, social=13, environment=7.6, (all p<0.01).1 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
 
Generalizability   
Shown to be valid at any stage of HD? Not assessed in HD. 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
- 
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Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
There were no significant treatment effects observed for WHOQOL-BREF between the Dance 
Dance Revolution and handheld video game interventions, and no significant differential 
treatment effects by disease severity. NOTE: values not given2 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects Unknown. 
Score distributions Unknown. 
IV. Overall impression 
Advantages  - 
Disadvantages  
This scale has been used in HD but no data are available regarding the scale from this trial.  As 
such, it would be similar to employing the WHOAOL 100 or any other generic quality of life 
scale in HD without any supportive data in this population.2 
Not suited to HD, a more suitable generic measure of QoL would be the WHODAS or 
PROMIS/Neuro-QoL, which are much better alternatives (judgment of the task force).  
V. Recommendation Listed 
 
 
 
References 
 
1. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric 
properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004;13:299-310. 
2. Kloos AD, Fritz NE, Kostyk SK, Young GS, Kegelmeyer DA. Video game play (Dance Dance Revolution) as a potential exercise 
therapy in Huntington's disease: a controlled clinical trial. Clinical rehabilitation 2013;27:972-82. 
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Quality of Life Index (QIL Index) 
I. Scale description 
Are there several versions of the scale?  Yes. There is a general form and many forms adapted for different condition.  
If you replied YES, which was been assessed? Unknown.1, 2 
Scale construct/ overall structure 
See in: https://qli.org.uic.edu  
 
The QLI was developed by Carol Estwing Ferrans and Marjorie Powers in 1984 to measure 
quality of life in terms of satisfaction with life. The QLI measures both satisfaction and 
importance regarding various aspects of life. 
  
The QLI produces five scores: quality of life overall and in four domains (health and 
functioning, psychological/spiritual domain, social and economic domain, and family). 
 
It has 33 items asked in two framework: on “how satisfied you are” and “how important is”? 
a. Question items    
Items of presence of symptom/sign? No. 
Items of severity of symptom/sign? Yes. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Discrete from 1 to 6. Different formulations in the two section. 
c. Is the scale easy to score? 
 
Approx. time to score patient  
 
d. Raters   
Patient, caregiver, or clinician Patient.  
If clinician-rated, is training for application required? Not applicable. 
e. Access to scale   
Copyright or public domain? Copyright. 
How can the scale be obtained (address or website)? 
See in: https://qli.org.uic.edu  
The QLI is made available through this website for use in non-profit research and non-profit 
clinical practice. 
Has the scale been published in other languages? 
 
Page 124 of 146
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction Unknown. 
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes (judgment of the task force). 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
No (judgment of the task force). 
Does it score current state or is it based on the 
patient/caregiver recall? 
 
What is the time frame (e.g. “during the past week”)?    
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Measure severity 
Is there a cut-off score? (for HD, for  non-HD) No 
d. Acceptability   
Is the length of the scale appropriate? A little long (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No (judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Yes (judgment of the task force). 
Is the scale applicable across HD disease stages?                                          
Are there HD stages in which the scale is not applicable? 
Unknown
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
It is a generic scale. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
No. 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  No. 
a. Reliability  
Assessed – not assessed Not assessed 
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Internal consistency - 
Test-retest reliability  - 
Inter-rater reliability  
- 
b. Validity in HD   
Assessed vs. not assessed Not assessed. 
Criterion validity (any comparison with gold-standard)  - 
Construct validity    
Factor analysis Not assessed in HD. 
Convergent validity Not assessed in HD. 
Divergent validity Not assessed in HD. 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
No information. 
Generalizability   
Shown to be valid at any stage of HD? 
Largest between-group differences were evident between spouses and their partners with early 
stage disease; and different QoL domains were impacted in the different participant groups. 
The data presented shows the QoL domains affected in each group; and the impact of specific 
neuropsychiatric, cognitive and motor symptoms on spouse partners. Identification of the 
specific domains impacted in spouse/partners at an early stage of disease is crucial for 
establishing appropriate and long-term support. 1, 2  
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Likely limited. 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
It is not sensitive to change over time after 12 months (TRACK-HD Study).1, 2 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No 
Floor and ceiling effects Unknown 
Score distributions Unknown. 
IV. Overall impression 
Advantages  - 
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Disadvantages  
There are virtually no data on this scale other than it has been used in a large HD study with 
some descriptive results. 
V. Recommendation Listed 
 
 
 
 
References 
 
1. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington's disease 
in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801. 
2. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, et al. Biological and clinical changes in premanifest and early stage 
Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-42. 
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Huntington Quality of Life Instrument (H-QoL-I)
1
 
I. Scale description 
Are there several versions of the scale?  No.  
If you replied YES, which was been assessed? Not applicable. 
Scale construct/ overall structure 
The H-QoL-I is a specific HRQoL tool.  
It consists of 11 items, which are divided into three dimensions rated from 0 - 100: motor 
functioning (four items), psychology (four items) and socializing (three items).1 
a. Question items    
Items of presence of symptom/sign? Yes.1 
Items of severity of symptom/sign? Yes.1 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Discrete steps (5, from never to always).1 
c. Is the scale easy to score? Yes. 
Approx. time to score patient  < 5 minutes. 
d. Raters   
Patient, caregiver, or clinician Patient. 
If clinician-rated, is training for application required? Not applicable 
e. Access to scale   
Copyright or public domain? Unclear. 
How can the scale be obtained (address or website)? From the original reporting paper.1 
Has the scale been published in other languages? French and Italian.1 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction 
Yes. 
1. A literature review identified the main relevant domains to be explored.  
2. A concept list was created in French after semi-structured interviews with patients, 
caregivers and HD healthcare professionals. 
3. A HD patient focus group came to a consensus on the aspects that impact the HRQoL 
of HD patients affected by HD.  
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4. Three domains were identified as crucial: motor functioning, psychology, and 
socializing.  
5. The questionnaire was developed in French, resulting in a long self-reported 
questionnaire.  
6. The most relevant items were kept. 
7. The final pre-version of the H-QoL-I included 42 Likert-type items and was translated 
into Italian using a forward–backward translation method.1 
8. ITEM REDUCTION: “ Before any item was excluded, its metrological properties and 
impact on the final instrument’s content were carefully considered.” 
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes.1 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
No.1 
Does it score current state or is it based on the 
patient/caregiver recall? 
Within the last two weeks.1 
What is the time frame (e.g. “during the past week”)?   Last two weeks.1 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Severity.1 
Is there a cut-off score? (for HD, for  non-HD) No. 
d. Acceptability   
Is the length of the scale appropriate? Yes (judgment of the task force). 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No judgment of the task force). 
Are there ambiguities in rating anchors? No (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
Yes (judgment of the task force). 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Yes.1 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
Yes.1 
e1. If yes to the above, has the scale been deployed in HD No. 
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by groups other than the developers? 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  Yes.1 
a. Reliability 
 
Assessed – not assessed Assessed in HD.1 
Internal consistency 
Manifest HD, n=252 
Motor functioning - Cronbach's alpha: 0.9. 
Psychology - Cronbach's alpha: 0.84. 
Socializing - Cronbach's alpha: 0.86.  
Test-retest reliability  Not reported. 
Inter-rater reliability  Not applicable. 
b. Validity in HD   
Assessed vs. not assessed Not reported. 
Overall impression: good – not good  Limited information for an impression. 
Criterion validity (any comparison with gold-standard)   
Construct validity    
Factor analysis 
Manifest HD, n=252 
Factor analysis with varimax rotation.  The items within factors with loadings of at least 0.50 
were considered to be significantly related to the factor. A three-factor solution accounted for 
75% of total variance with varimax rotation (22.4-27.9%%).1 
Convergent validity 
Manifest HD, n=252 
Correlations of 0.5-0.7 with a variety of other quality of life instruments.1 
Divergent validity - 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
Not good (judgment of the task force). 
Generalizability   
Shown to be valid at any stage of HD? Not reported. 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Not assessed. 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time Not assessed. 
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or to treatment)? 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects 
Manifest HD, n=252
1
 
Socializing = floor effect of 32%.  
Motor function = Ceiling effect of 16.6 %. 
Score distributions Acceptable.1 
IV. Overall impression 
Advantages  Very simple to use. 
Disadvantages  
Language issues (developed in French and Italian translated into English) and limited data 
available at this time. 
V. Recommendation Listed 
 
 
 
References 
 
1. Clay E, De Nicola A, Dorey J, Squitieri F, Aballea S, Martino T, et al. Validation of the first quality-of-life measurement for patients with 
Huntington's disease: the Huntington Quality of Life Instrument. Int Clin Psychopharmacol 2012;27:208-14. 
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HD-Pro-TRIAD 
I. Scale description 
Are there several versions of the scale?  No  
If you replied YES, which was been assessed? - 
Scale construct/ overall structure 
47 items comprising 14 for cognition, 14 for emotional and behavioral dyscontrol and 19 for 
motor function. These 47 items are drawn from other instruments i.e., Neuro-QOL, Traumatic 
Brain Injury - QoL, HDQLIFE, FACIT.1 
a. Question items    
Items of presence of symptom/sign? Yes. 
Items of severity of symptom/sign? Yes. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
5 discrete steps. 
c. Is the scale easy to score? 
 
Approx. time to score patient  5 minutes. 
d. Raters   
Patient, caregiver, or clinician Patient, caregiver. 
If clinician-rated, is training for application required? Not applicable 
e. Access to scale   
Copyright or public domain? Public domain. 
How can the scale be obtained (address or website)? From the original article.1 
Has the scale been published in other languages? Constituent items are from scales with language translations. 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction 
1. A literature review was performed to define the triad of symptoms relevant to a HD-
specific health-related QoL instrument. 
2.  Phone interviews with HD patients and caregivers. 
3. An expert survey was conducted to identify HRQOL issues important to individuals 
with HD and develop items for a preliminary version of HD-PRO-TRIAD.  
4. Relevant items from the Neuro-QOL, the Traumatic Brain Injury-QOL, the HDQLIFE 
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and the Functional Assessment of Chronic Illness Therapy (FACIT) were included. 
5. Content was matched with patient, caregiver, and provider perspectives. 
6. A preliminary instrument was cognitively tested in 10 individuals with HD.1, 2 
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes (judgment of the task force). 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
No (judgment of the task force). 
Does it score current state or is it based on the 
patient/caregiver recall? 
Patient and caregiver recall.1, 2 
What is the time frame (e.g. “during the past week”)?   Past 7 days. 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Measure severity. 
Is there a cut-off score? (for HD, for  non-HD) No. 
d. Acceptability   
Is the length of the scale appropriate? It is long (47 questions). (Judgment of the task force) 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
Yes (judgment of the task force). 
Are there ambiguities in rating anchors? Yes (judgment of the task force). 
Are the questions appropriate for use in an HD 
population? 
No (judgment of the task force). 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Limited information is available about the online self-report (judgment of the task force). 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
Yes. 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
No. 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  Limited. 
a. Reliability 
 
Assessed – not assessed Assessed in HD. 
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Internal consistency 
Manifest HD, n=132.
1
  
HD-PRO-TRIAD TOTAL - Cronbach’s alpha 0.98; 
HD-PRO-TRIAD Cognition - Cronbach’s alpha 0.97; 
HD-PRO-TRIAD Emotional/Behavioral - Cronbach’s alpha 0.96; 
HD-PRO-TRIAD Motor Function - Cronbach’s alpha 0.98; 
 
NOTE: item-total correlations from 0.54 to 0.84.1 
Test-retest reliability  No 
Inter-rater reliability  Not applicable. 
b. Validity in HD   
Assessed vs. not assessed Assessed. 
Criterion validity (any comparison with gold-standard)  - 
Construct validity    
Factor analysis No. 
Convergent validity 
Manifest HD, n=132.
1
  
Motor - SOME EVIDENCE: 0.77 with Neuro-QoL lower extremity, 0.81 with Neuro-QoL 
upper extremity, 0.83 with PROMIS global physical health, 0.77 with SF-Physical, 0.77 with 
EQ-5D, 0.77 with TFC, 0.58 with IS; and 0.62. 0.61. 0.55 with NeuroQoL Anxiety, 
Depression & Social roles, 0.72 with PROMIS global mental health, 0.61 with SF Mental) 
 
Emotional/behavioral dyscontrol domains (0.75. 0.75, 0.27 with NeuroQoL Anxiety, 
Depression & Social Roles - SOME EVIDENCE: 0.73 with PROMIS global mental health, 
0.53 with SF Mental; and 0.45 with Neuro-QoL lower extremity, 0.44 with Neuro-QoL upper 
extremity, 0.57 with PROMIS global physical health, 0.47 with SF-Physical, 0.49 with EQ-5D, 
0.40 with TFC, 0.35 with IS). 
 
Cognition – LIMITED  (no cognitive measures and highest correlations were for NeuroQoL 
upper extremity (0.81) and PROMIS global physical health (0.80).1 
Divergent validity - 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
Limited data. 
Generalizability   
Shown to be valid at any stage of HD? No. 
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Shown to be valid in any population with dementia or 
significant cognitive impairment? 
No. 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
No. 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects 
Unknown. 
 
Score distributions 
Manifest HD, n=132.1  
HD-PRO-TRIAD Cognition - 3.2 (1.1). 
HD-PRO-TRIAD Emotional/Behavioral - 2.7 (1.0). 
HD-PRO-TRIAD Motor Function - 2.9 (1.0). 
IV. Overall impression 
Advantages  Inclusion of generic and HD-specific contents. 
Disadvantages  
Online study with unverified self-reported clinical characteristics.  
Cognition scale not examined against cognitive assessments for concurrent validity. More data 
are needed for convergent and discriminant validity. 
V. Recommendation Listed 
 
 
 
 
References 
 
1. Carlozzi NE, Victorson D, Sung V, Beaumont JL, Cheng W, Gorin B, et al. HD-PRO-TRIAD Validation: A Patient-reported Instrument 
for the Symptom Triad of Huntington's Disease. Tremor Other Hyperkinet Mov (N Y) 2014;4:223. 
2. Victorson D, Carlozzi NE, Frank S, Beaumont JL, Cheng W, Gorin B, et al. Identifying Motor, Emotional-Behavioral, and Cognitive 
Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives. Tremor Other Hyperkinet Mov (N Y) 
2014;4:224. 
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CAREGIVER FOCUSED 
 
The Alzheimer’s Carer’s Quality of Life Inventory (ACQLI) 
I. Scale description 
Are there several versions of the scale?  
No.1 
 
If you replied YES, which was been assessed? Not applicable. 
Scale construct/ overall structure 
Assesses quality of life (QoL) of Alzheimer’s disease (AD) caregivers; needs-based QoL 
model; assessed by AD caregivers from 5 countries.1 
30 items are scored 0/1 (not true/true); summed into a total score with a 0–30 range.1 
http://www.galen-
research.com/content/measures/ACQLI%20UK%2030%20Male%20Patient%20-
%20First%20page%20sample.pdf 
a. Question items    
Items of presence of symptom/sign? Presence or absence of symptoms. 
Items of severity of symptom/sign? Unknown. 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Binary: yes or no. 
c. Is the scale easy to score? 
 
Approx. time to score patient  5 minutes (judgment of the task force). 
d. Raters   
Patient, caregiver, or clinician Patient. 
If clinician-rated, is training for application required? Not applicable. 
e. Access to scale   
Copyright or public domain? Copyright, Galen Research and Glaxo SmithKline. 
How can the scale be obtained (address or website)? 
From Mapi: https://eprovide.mapi-trust.org/index.php/instruments/alzheimer-s-carer-s-quality-
of-life-instrument 
Has the scale been published in other languages? 
9 translations https://eprovide.mapi-trust.org/index.php/instruments/alzheimer-s-carer-s-
quality-of-life-instrument 
Includes English, French, German, Italian and Spanish.2 
II. Scale properties 
a. Content validity 
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Any process for item generation and/or reduction 
In-depth qualitative interviews conducted with 40 carers in the UK.2 
Items were translated for use in each of the languages with emphasis on producing conceptual 
equivalence.  
Field-testing of the measure in each country indicated that the respondents found it acceptable, 
relevant and easy to complete.  
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes (judgment of the task force).1 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
No (judgment of the task force).1 
Does it score current state or is it based on the 
patient/caregiver recall? 
Current state. 
What is the time frame (e.g. “during the past week”)?   Current time. 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain? 
Assess severity of caregiver burden.1 
Is there a cut-off score? (for HD, for  non-HD) No. 
d. Acceptability   
Is the length of the scale appropriate? Yes.1 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
Note: the task force was unable to procure a copy of the scale. 
Are there ambiguities in rating anchors? Not applicable. 
Are the questions appropriate for use in an HD 
population? 
Appropriate for HD caregivers.1 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Applicable for caregivers of all HD stages (judgment of the task force).  
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
No.1 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Not applicable. 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  Yes. 
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a. Reliability 
 
Assessed – not assessed Assessed in HD. 
Internal consistency 
61 HD Caregivers: 
Coefficient alpha = 0.95.1 
Test-retest reliability  Not assessed in HD. 
Inter-rater reliability  Not assessed in HD. 
b. Validity in HD   
Assessed vs. not assessed Not assessed in HD. 
Overall impression: good – not good  Limited information 
Criterion validity (any comparison with gold-standard)   
Construct validity    
Factor analysis N/A, unidimensional scale.1 
Convergent validity Not assessed in HD. 
Divergent validity Not assessed in HD. 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
Not good (judgment of the task force). 
Generalizability   
Shown to be valid at any stage of HD? Not applicable 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Not applicable 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
Not assessed in HD. 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects 
61 HD Caregivers: 
Acceptable: 9.8% floor effect, 1.6% ceiling effect.1 
Score distributions 
61 HD Caregivers: 
42 (29.5)1 
IV. Overall impression 
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Advantages  Quick, easy to use assessment. 
Disadvantages  Further clinimetric testing is required. 
V. Recommendation Suggested for assessing quality of life for HD caregivers (severity) 
 
 
 
References 
 
1. Hagell P, Smith S. A psychometric comparison of two carer quality of life questionnaires in Huntington's disease: implications for 
neurodegenerative disorders. J Huntingtons Dis 2013;2:315-22. 
2. Doward LC. The Development of the Alzheimer's Carers' Quality of Life Instrument Quality of Life Research 1997;6:639. 
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Huntington's disease quality of life battery for carers (HD-QoL C) 
I. Scale description 
Are there several versions of the scale?  Yes, short (20-item) and long (34-item) forms are available.1 
If you replied YES, which was been assessed? Both. 
Scale construct/ overall structure 
The HDQoL-C is a HD-specific, multi- dimensional and validated tool for measuring quality 
of life (QoL) in family caregivers of patients with HD.  
 
It is based upon the domains and facets of the Comprehensive Quality of Life scale for adults 
(ComQol-A5).2 
 
The 34-item version covers three domains: “practical aspects of caregiving” (n=9), 
“satisfaction with life” (n=8) and “feelings about living with HD” (n=17). 
 
The 20-item version comprises: 3-items on “satisfaction of life” and all items from “feelings 
about living with HD” (n=17). 
 
Long-form: 11-grade (0–10) numerical rating scale, summed and transformed into a 0–100 
range, (100 = better QoL); total score = is computed as the overall sum, transformed into a 0–
100 range (100 = better QoL). 
Short-form: item scores are summed and transformed into a 0–100 range (100 = better QoL) 
for each suggested subscale. 
a. Question items    
Items of presence of symptom/sign? Yes.3 
Items of severity of symptom/sign? Frequency is assessed, as well as satisfaction, but not severity.3 
b. Response scale   
Are the items of the scale scored in discrete steps (specify 
number) or in a visual analogue scale? 
Discrete steps: 11.3 
c. Is the scale easy to score? 
 
Approx. time to score patient  
Total time (scoring and administration time): 27 minutes.  
Instructions exist on how to set up a syntax, which would make it quicker to score.3 
d. Raters   
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Patient, caregiver, or clinician Caregiver.3 
If clinician-rated, is training for application required? Not applicable 
e. Access to scale   
Copyright or public domain? Copyright. 
How can the scale be obtained (address or website)? From the original author: Aimee Aubeeluck. 3 
Has the scale been published in other languages? Yes, 3 languages.3 
II. Scale properties 
a. Content validity 
 
Any process for item generation and/or reduction 
1) The HDQoL-C was developed using the data gathered from our three preliminary 
investigations and the existing domains and facets of the COMQOL-A5.3 
2) A number of items were revised or removed from the scale as they were not deemed as 
pertinent to the HD spousal caregivers QoL. 
3) From the 63 items in the pilot version of the HDQoL-C, 27 items were accepted, four items 
were revised, one item was rewritten and 31 were discarded. Two qualitative questions were 
also added to the HDQoL-C in line with comments from experts and carers. 
b. Face validity    
Do the items of the scale cover different components of 
the specific domain? 
Yes. 
Is the scale heavily weighted towards one aspect of the 
domain it measures and which components of the domain 
are not covered? 
There are more items on feelings about life (17); satisfaction with life has 8 questions, aspects 
of caring 9 questions.3 
Does it score current state or is it based on the 
patient/caregiver recall? 
Current state.3 
What is the time frame (e.g. “during the past week”)?   Not specified.3 
c. Use   
Purpose: to measure severity, screen or diagnosis of the 
domain?  
Is there a cut-off score? (for HD, for  non-HD) 
No. 
 
NOTE: there are instructions on interpreting the scores: 3  
 
“A high score (119 or more) would suggest how you feel is having very little impact on your 
quality of life. 
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A middle score (between 69 and 118) would suggest how you feel is having a moderate impact 
on your quality of life. 
 
A low score (68 or less) would suggest how you feel is having a big impact on your quality of 
life.”  
d. Acceptability   
Is the length of the scale appropriate? A little long, but not excessively (judgment of the task force).3 
Are there ambiguities in instructions to patient/rater (as 
applicable)? 
No.3 
Are there ambiguities in rating anchors? Not applicable. 
Are the questions appropriate for use in an HD 
population? 
For HD caregivers, yes.3 
Is the scale applicable across HD disease stages?                                              
Are there HD stages in which the scale is not applicable? 
Caregiver scale.3 
e. Has this scale been specifically developed for use in HD 
(yes/no)? 
Yes.3 
e1. If yes to the above, has the scale been deployed in HD 
by groups other than the developers? 
Yes. 
III. Clinimetric/psychometric properties  
 
Are there  clini- or psychometric properties in HD ?  Yes. 
a. Reliability 
 
Assessed – not assessed Assessed in HD caregivers. 
Internal consistency 
Long-form: Cronbach’s alpha  “Practical aspects of caregiving”: 0.62; “Satisfaction with life”: 
0.91; “Feelings about living with HD”, 0.84.4 
Cronbach’s alpha: Component 2, 0.801; Component 3, 0.844; Component 4, 0.885. Total, 
0.92.3 
Short-form: Cronbach’s alpha, Satisfaction with life, 0.92; total, 0.88.4 
Test-retest reliability  
10 carers completed the HDQoL-C two weeks after first administration.  
Both questionnaire scores were subsequently correlated using Pearson’s correlation coefficient: 
component 2, r=0.86; component 3, r=0.90; component 4, r=0.92.3 
Inter-rater reliability  - 
b. Validity in HD   
Assessed vs. not assessed Assessed in HD caregivers. 
Page 143 of 146
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Criterion validity (any comparison with gold-standard)  - 
Construct validity    
Factor analysis 
Principal components analysis (PCA)3 PCA revealed the presence of seven subscales 
subsumed within the three components of practical aspects of care-giving’, satisfaction with 
life’ and feelings about living with HD.3  
Convergent validity 
Correlations with WHO-QoL BREF.
3
 
Pearson’s correlation coefficient of 0,0.58, p<0.01 for component (practical aspects of 
caregiving), of 0.64, p<0.01 for component (satisfaction with life) and of 0.76, p<0.01 for 
component (feelings about living with HD). 
Correlations of 0.22 to 0.28 with H-QoL-I.
5
 
Divergent validity 
 
Overall impression: good – not good  (based on references 
preferably, judgment of the task force can be stated) 
OK, and can be considered if performing a study on caregivers, but more established measures 
from other caregiving populations may be considered.  (Judgment of the task force). 
Generalizability   
Shown to be valid at any stage of HD? Not applicable. 
Shown to be valid in any population with dementia or 
significant cognitive impairment? 
Not applicable 
Responsiveness (detect change over time in the construct)  
Demonstrated to be sensitive to change (change over time 
or to treatment)? 
No. 
Interpretability  
Has the minimal clinically important change and minimal 
clinically relevant incremental difference been assessed? 
No. 
Floor and ceiling effects 
Long-form: “Practical aspects of caregiving”: 0/0; “Satisfaction with life”: 3.3/0; “Feelings 
about living with HD”: 0/0 Total 0/0 (all okay 15-205 set as maximum).4 
Short-form: “Satisfaction with life”: 6.6/1.6 and total 0/0 (both okay).4 
Score distributions 
Long-form: 49.6 (16.8).4 
Short-form: 49.5 (18.2).4 
IV. Overall impression 
Advantages  Specific for HD. 
Disadvantages  Reduced uptake. 
V. Recommendation Suggested for assessing quality of life for HD caregivers (severity) 
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